Stereotaxis (STXS) 10-K 27 Mar 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Feb. 28, 2014	Jun. 30, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2013	'	'
Entity Registrant Name	'Stereotaxis, Inc.	'	'
Entity Central Index Key	'0001289340	'	'
Current Fiscal Year End Date	'--12-31	'	'
Trading Symbol	'stxs	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Common Stock, Shares Outstanding	'	19,308,125	'
Entity Public Float	'	'	$6.80

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$13,775,130	$7,777,718
Accounts receivable, net of allowance of $383,077 and $640,183 in 2013 and 2012, respectively	7,558,152	11,570,489
Inventories	4,879,039	5,098,241
Prepaid expenses and other current assets	1,945,206	3,492,067
Total current assets	28,157,527	27,938,515
Property and equipment, net	1,184,589	2,141,923
Intangible assets, net	1,679,486	1,979,320
Long-term receivables	20,431	73,199
Other assets	34,363	32,987
Total assets	31,076,396	32,165,944
Current liabilities:	'	'
Short-term debt and current maturities of long-term debt	49,733	12,264,490
Accounts payable	3,512,339	3,556,688
Accrued liabilities	7,079,381	5,361,810
Deferred revenue	7,519,754	9,502,939
Warrants and debt conversion features	5,644,626	2,968,348
Total current liabilities	23,805,833	33,654,275
Long-term debt, less current maturities	18,481,478	16,824,736
Long-term deferred revenue	491,080	477,159
Stockholders' deficit:	'	'
Preferred stock, par value $0.001; 10,000,000 shares authorized, none outstanding at 2013 and 2012	'	'
Common stock, par value $0.001; 300,000,000 shares authorized, 19,311,390 and 8,018,615 shares issued at 2013 and 2012, respectively	19,311	8,019
Additional paid in capital	441,888,155	366,053,627
Treasury stock, 4,015 shares at 2013 and 2012	-205,999	-205,999
Accumulated deficit	-453,403,462	-384,645,873
Total stockholders' deficit	-11,701,995	-18,790,226
Total liabilities and stockholders' deficit	$31,076,396	$32,165,944

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Balance Sheets [Abstract]	'	'
Accounts receivable, allowance	$383,077	$640,183
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	19,311,390	8,018,615
Treasury stock, shares	4,015	4,015

Statements_Of_Operations

Statements Of Operations (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenue:	'	'	'
Systems	$12,743,218	$19,672,983	$15,585,538
Disposables, service and accessories	25,287,863	26,889,451	26,401,894
Total revenue	38,031,081	46,562,434	41,987,432
Cost of revenue:	'	'	'
Systems	6,870,954	9,905,528	8,576,283
Disposables, service and accessories	4,130,347	4,875,527	3,921,798
Total cost of revenue	11,001,301	14,781,055	12,498,081
Gross margin	27,029,780	31,781,379	29,489,351
Operating expenses:	'	'	'
Research and development	5,672,058	8,405,086	12,886,488
Sales and marketing	17,132,093	20,607,999	31,635,415
General and administrative	13,066,103	13,394,556	16,908,656
Total operating expenses	35,870,254	42,407,641	61,430,559
Operating loss	-8,840,474	-10,626,262	-31,941,208
Other income (expense)	-47,349,378	8,265,507	3,416,383
Interest income	5,800	7,361	9,052
Interest expense	-12,573,537	-6,885,033	-3,515,402
Net loss	($68,757,589)	($9,238,427)	($32,031,175)
Net loss per common share:	'	'	'
Basic	($5.95)	($1.33)	($5.84)
Diluted	($5.95)	($1.33)	($5.84)
Weighted average shares used in computing net loss per common share:	'	'	'
Basic	11,554,566	6,944,928	5,482,627
Diluted	11,554,566	6,944,928	5,482,627

Statements_Of_Stockholders_Equ

Statements Of Stockholders' Equity (USD $)	Common Stock [Member]	Additional Paid-In Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Total
Stockholders' Equity Attributable to Parent, Beginning Balance at Dec. 31, 2010	$5,475	$354,052,041	($205,999)	($343,376,271)	$10,475,246
Shares, issued, beginning balance at Dec. 31, 2010	5,474,624	'	'	'	'
Issuance of common stock and warrants, value	8	-8	'	'	'
Issuance of common stock and warrants, shares	8,400	'	'	'	'
Share-based compensation, value	'	2,487,441	'	'	2,487,441
Issuance of stock under purchase plan, value	9	232,382	'	'	232,391
Issuance of stock under purchase plan, shares	8,449	'	'	'	'
Exercise of stock options, value	'	7,202	'	'	7,202
Exercise of options/SAR's, shares	468	'	'	'	'
Grant of restricted shares, net of forfeitures, value	51	-51	'	'	'
Grant of restricted shares, net of forfeitures, shares	51,216	'	'	'	'
Net Loss	'	'	'	-32,031,175	-32,031,175
Stockholders' Equity Attributable to Parent, Ending Balance at Dec. 31, 2011	5,543	356,779,007	-205,999	-375,407,446	-18,828,895
Shares, issued, ending balance at Dec. 31, 2011	5,543,157	'	'	'	'
Issuance of common stock and warrants, value	2,415	10,409,260	'	'	10,411,675
Issuance of common stock and warrants, shares	2,415,339	'	'	'	'
Share-based compensation, value	'	2,293,731	'	'	2,293,731
Issuance of stock under purchase plan, value	10	73,543	'	'	73,553
Issuance of stock under purchase plan, shares	10,315	'	'	'	'
Grant of restricted shares, net of forfeitures, value	20	-20	'	'	'
Grant of restricted shares, net of forfeitures, shares	19,885	'	'	'	'
Restricted stock vestings, value	31	-31	'	'	'
Restricted stock vestings, shares	29,919	'	'	'	'
Reclassification of warrants to liability	'	-3,501,863	'	'	-3,501,863
Net Loss	'	'	'	-9,238,427	-9,238,427
Stockholders' Equity Attributable to Parent, Ending Balance at Dec. 31, 2012	8,019	366,053,627	-205,999	-384,645,873	-18,790,226
Shares, issued, ending balance at Dec. 31, 2012	8,018,615	'	'	'	'
Issuance of common stock and warrants, value	7,743	64,586,770	'	'	64,594,513
Issuance of common stock and warrants, shares	7,742,717	'	'	'	'
Share-based compensation, value	'	1,050,260	'	'	1,050,260
Exercise of options/SAR's, shares	'	'	'	'	145
Rights offering, value	3,400	10,197,647	'	'	10,201,047
Rights offering, shares	3,400,349	'	'	'	'
Grant of restricted shares, net of forfeitures, value	-62	62	'	'	'
Grant of restricted shares, net of forfeitures, shares	-61,910	'	'	'	'
Restricted stock vestings, value	211	-211	'	'	'
Restricted stock vestings, shares	211,619	'	'	'	'
Net Loss	'	'	'	-68,757,589	-68,757,589
Stockholders' Equity Attributable to Parent, Ending Balance at Dec. 31, 2013	$19,311	$441,888,155	($205,999)	($453,403,462)	($11,701,995)
Shares, issued, ending balance at Dec. 31, 2013	19,311,390	'	'	'	'

Statements_Of_Cash_Flows

Statements Of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities	'	'	'
Net loss	($68,757,589)	($9,238,427)	($32,031,175)
Adjustments to reconcile net loss to cash used in operating activities:	'	'	'
Depreciation	919,136	1,300,188	1,462,238
Amortization of intangibles	299,833	299,833	299,833
Amortization of deferred finance costs and debt discounts	7,703,336	2,977,119	1,331,549
Share-based compensation	1,050,260	2,293,731	2,487,441
Non-cash royalty (income), net	'	'	-2,353,718
Gain on debt conversion	'	-75,612	'
Loss on asset disposal	36,103	12,444	86,278
Adjustment of warrants and convertible debt features	47,450,066	-8,189,895	-3,416,383
Interest due from issuance of stock	551,296	192,128	'
Changes in operating assets and liabilities:	'	'	'
Accounts receivable	4,013,279	-447,613	2,811,531
Other receivables	51,827	19,534	28,495
Inventories	219,202	937,810	-594,576
Prepaid expenses and other current assets	429,025	-760,474	827,297
Other assets	-1,376	7,773	-2,223
Accounts payable	-44,349	-2,053,493	-3,186,001
Accrued liabilities	1,717,571	-514,689	-1,090,072
Deferred revenue	-1,969,264	1,125,079	1,775,856
Other liabilities	'	-3,094	-5,648
Net cash used in operating activities	-6,331,644	-12,117,658	-31,569,278
Cash flows from investing activities	'	'	'
Purchase of equipment	'	-130,699	-1,031,749
Net cash used in investing activities	'	-130,699	-1,031,749
Cash flows from financing activities	'	'	'
Payments of term note	-4,000,000	-4,000,000	-2,000,000
Proceeds from revolving line of credit	37,237,131	54,806,154	77,109,376
Payments of revolving line of credit	-44,490,148	-62,842,934	-72,818,866
Proceeds from subordinated convertible debt, net of issuance costs	'	7,738,351	'
Proceeds from Healthcare Royalty Partners debt	2,546,328	2,500,000	14,317,397
Payments of Healthcare Royalty Partners debt	-263,192	-1,252,647	'
Payments of Biosense Debt	'	'	-5,540,373
Proceeds from issuance of stock and warrants, net of issuance costs	21,298,937	9,122,232	239,593
Net cash provided by financing activities	12,329,056	6,071,156	11,307,127
Net increase (decrease) in cash and cash equivalents	5,997,412	-6,177,201	-21,293,900
Cash and cash equivalents at beginning of period	7,777,718	13,954,919	35,248,819
Cash and cash equivalents at end of period	13,775,130	7,777,718	13,954,919
Supplemental disclosures of cash flow information:	'	'	'
Interest Paid	$3,187,353	$3,258,900	$859,494

Description_Of_Business

Description Of Business	12 Months Ended
	Dec. 31, 2013
Description Of Business [Abstract]	'
Description Of Business	'
	1. Description of Business
	Stereotaxis designs, manufactures and markets the Epoch Solution, which is an advanced remote robotic navigation system for use in a hospital’s interventional surgical suite, or “interventional lab”, that we believe revolutionizes the treatment of arrhythmias and coronary artery disease by enabling enhanced safety, efficiency and efficacy for catheter-based, or interventional, procedures.  The Epoch Solution is comprised of the Niobe ES Robotic Magnetic Navigation System (“Niobe ES system”), Odyssey Information Management Solution (“Odyssey Solution”), and the Vdrive Robotic Navigation System (“Vdrive system”).
	The Niobe system is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, efficient procedures and reduced x-ray exposure.
	In addition to the Niobe system and its components, Stereotaxis also has developed the Odyssey Solution, which consolidates all lab information enabling doctors to focus on the patient for optimal procedure efficiency. The system also features a remote viewing and recording capability called Odyssey Cinema, which is an innovative solution delivering synchronized content for optimized workflow, advanced care and improved productivity. This tool includes an archiving capability that allows clinicians to store and replay entire procedures or segments of procedures. This information can be accessed from locations throughout the hospital local area network and over the global Odyssey Network providing physicians with a tool for clinical collaboration, remote consultation and training.
	Our Vdrive system provides navigation and stability for diagnostic and therapeutic devices designed to improve interventional procedures. The Vdrive system complements the Niobe ES system control of therapeutic catheters for fully remote procedures and enables single-operator workflow and is sold as two options, the Vdrive system and the Vdrive Duo system. In addition to the Vdrive system and the Vdrive Duo system, we also manufacture and market various disposable components which can be manipulated by these systems.
	We promote the full Epoch Solution in a typical hospital implementation, subject to regulatory approvals or clearances. The full Epoch Solution implementation requires a hospital to agree to an upfront capital payment and recurring payments. The upfront capital payment typically includes equipment and installation charges. The recurring payments typically include disposable costs for each procedure, equipment service costs beyond warranty period, and software licenses. In hospitals where the full Epoch Solution has not been implemented, equipment upgrade or expansion can be implemented upon purchasing of the necessary upgrade or expansion.
	The core components of Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere; V-Sono ICE Catheter Manipulator has received U.S. regulatory clearance and the V-Loop Circular Catheter Manipulator is expected to be submitted for review by the U.S. Food and Drug Administration in early 2014.
	Since our inception, we have generated significant losses. As of December 31 2013, we had incurred cumulative net losses of approximately $453.4 million. In May 2011, the Company introduced the Niobe ES system and as of December 31, 2013, the Company had an installed base of 100 Niobe ES systems and has received positive feedback from the physicians at these sites.  Between 2011 and 2013, the Company implemented a wide ranging plan to rebalance and reduce operating expenses by 15%  to 20% on an annual run rate basis. We expect to incur additional losses into 2014 as we continue the development and commercialization of our products, conduct our research and development activities and advance new products into clinical development from our existing research programs and fund additional sales and marketing initiatives. During 2014, we expect operating expenses to be generally consistent with 2013 with additional investment in certain targeted areas.
	We may be required to raise capital or pursue other financing strategies to continue our operations. Until we can generate significant cash flow from our operations, we expect to continue to fund our operations with cash resources primarily generated from the proceeds of our past and future public offerings, private sales of our equity securities and working capital and equipment financing loans. In the future, we may finance cash needs through the sale of other equity securities or non-core assets, strategic collaboration agreements, debt financings or through distribution rights. We cannot accurately predict the timing and amount of our utilization of capital, which will depend on a number of factors outside of our control.
	Our existing cash, cash equivalents and borrowing facilities may not be sufficient to fund our operating expenses and capital equipment requirements through the next 12 months, which would require us to obtain additional financing before that time. Further, our revolving line of credit with Silicon Valley Bank matures on March 31, 2014. We cannot assure that additional financing will be available on a timely basis on terms acceptable to us or at all, or that such financing will not be dilutive to our stockholders.  If adequate funds are not available to us, we could be required to delay development or commercialization of new products, to license to third parties the rights to commercialize products or technologies that we would otherwise seek to commercialize ourselves or to reduce the sales, marketing, customer support or other resources devoted to our products, any of which could have a material adverse effect on our business, financial condition and results of operations. In addition, we could be required to cease operations.

Summary_Of_Significant_Account

Summary Of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Summary Of Significant Accounting Policies [Abstract]	'
Summary Of Significant Accounting Policies	'
	2. Summary of Significant Accounting Policies
	Cash and Cash Equivalents
	The Company considers all short-term investments purchased with original maturities of three months or less to be cash equivalents. The Company places its cash with high-credit-quality financial institutions and invests primarily in money market accounts. In 2012, we entered into a letter of credit to support a commitment in the amount of approximately $0.1 million. This letter of credit is valid through 2015. No cash was restricted at December 31, 2013 or 2012.
	Accounts Receivable and Allowance for Uncollectible Accounts
	Accounts receivable primarily include amounts due from hospitals and distributors for acquisition of magnetic systems, associated disposable device sales and service contracts. Credit is granted on a limited basis, with balances due generally within 30 days of billing. The provision for bad debts is based upon management’s assessment of historical and expected net collections considering business and economic conditions and other collection indicators.
	Financial Instruments
	Financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and debt. The carrying value of such amounts reported at the applicable balance sheet dates approximates fair value. See Note 9 for disclosure of the fair value of debt.
	The Company measures certain financial assets and liabilities at fair value on a recurring basis, including warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”).  See Note 12 for disclosure of fair value measurements.
	Inventory
	The Company values its inventory at the lower of cost, as determined using the first-in, first-out (FIFO) method, or market. The Company periodically reviews its physical inventory for obsolete items and provides a reserve upon identification of potential obsolete items.
	Property and Equipment
	Property and equipment consist primarily of computer, office, and research and demonstration equipment held for lease and leasehold improvements and are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives or life of the base lease term, ranging from three to ten years.
	Long-Lived Assets
	If facts and circumstances suggest that a long-lived asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value.
	Intangible Assets
	Intangible assets consist of purchased technology and intellectual property rights valued at cost on the acquisition date and amortized over their estimated useful lives of 10-15 years. If facts and circumstances suggest that an intangible asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and loss during the reporting period. Actual results could differ from those estimates.
	Revenue and Costs of Revenue
	The Company adopted Accounting Standards Update 2009-13, Multiple-Deliverable Revenue Arrangements (“ASU 2009-13”) in the fourth quarter of 2009, effective as of January 1, 2009.
	ASU 2009-13 permits management to estimate the selling price of undelivered components of a bundled sale for which it is unable to establish vendor-specific objective evidence (“VSOE”) or third-party evidence (“TPE”). This requires management to record revenue for certain elements of a transaction even though it might not have delivered other elements of the transaction, for which it was unable to meet the requirements for establishing VSOE or TPE. The Company believes that the guidance significantly improves the reporting of these types of transactions to more closely reflect the underlying economic circumstances. This guidance also prohibits the use of the residual method for allocating revenue to the various elements of a transaction and requires that the revenue be allocated proportionally based on the relative estimated selling prices.
	Under our revenue recognition policy, a portion of revenue for Niobe systems, Vdrive systems and certain Odyssey systems is recognized upon delivery, provided that title has passed, there are no uncertainties regarding acceptance, persuasive evidence of an arrangement exists, the sales price is fixed and determinable, and collection of the related receivable is reasonably assured. Revenue is recognized for other types of Odyssey systems upon completion of installation, since there are no qualified third party installers.  When installation is the responsibility of the customer, revenue from system sales is recognized upon shipment since these arrangements do not include an installation element or right of return privileges.  The Company does not recognize revenue in situations in which inventory remains at a Stereotaxis warehouse or in situations in which title and risk of loss have not transferred to the customer. Amounts collected prior to satisfying the above revenue recognition criteria are reflected as deferred revenue.  Revenue from services and license fees, whether sold individually or as a separate unit of accounting in a multiple-deliverable arrangement, is deferred and amortized over the service or license fee period, which is typically one year. Revenue from services is derived primarily from the sale of annual product maintenance plans. We recognize revenue from disposable device sales or accessories upon shipment and establish an appropriate reserve for returns. The return reserve, which is applicable only to disposable devices, is estimated based on historical experience which is periodically reviewed and updated as necessary. In the past, changes in estimate have had only a de minimus effect on revenue recognized in the period. We believe that the estimate is not likely to change significantly in the future.
	Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred.
	Research and Development Costs
	Internal research and development costs are expensed in the period incurred. Amounts receivable from strategic alliances under research reimbursement agreements are recorded as a contra-research and development expense in the period reimbursable costs are incurred. There were no material receivables at December 31, 2013 or 2012 under these types of agreements. Advance receipts or other unearned reimbursements are included in accrued liabilities on the accompanying balance sheet until earned.
	Share-Based Compensation
	Stock options or stock appreciation rights issued to certain non-employees are recorded at their fair value as determined in accordance with general accounting principles for share-based payments and accounting for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services, and recognized over the service period. Deferred compensation for options granted to non-employees is remeasured on a quarterly basis through the vesting or forfeiture date.
	The Company utilized the Black-Scholes valuation model to determine the fair value of share-based payments at the date of previously issued grant using risk-free interest rate based on the Treasury yield on the date of the grant and expected volatility based on the Company’s historical volatility over the expected term of the option. The resulting compensation expense is recognized over the requisite service period, generally one to four years. Compensation expense is recognized only for those awards expected to vest, with forfeitures estimated based on the Company’s historical experience and future expectations.
	Restricted shares granted to employees are valued at the fair market value at the date of grant. The Company amortizes the amount to expense over the service period on a straight-line basis for those shares with graded vesting. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives.
	Shares purchased by employees under the 2004 Employee Stock Purchase Plan were considered to be compensatory and were accounted for in accordance with general accounting principles for share-based payments.
	Net Loss per Common Share
	Basic loss per common share is computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed by dividing the loss for the period by the weighted average number of common and common equivalent shares outstanding during the period. In addition, the application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable because the Company’s unearned restricted shares do not contractually participate in its losses.
	The Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights or warrants in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because those securities do not contractually participate in its losses.
	On July 10, 2012, the Company effected a one-for-ten reverse stock split of the Company’s common stock.  The net loss per common share, shares outstanding, and weighted average shares outstanding reported in the financial statements and notes to the financial statements for the periods ending December 31, 2013, 2012, and 2011 are presented on a post-split basis.  See Note 11 for additional discussion of the reverse stock split.
	As of December 31, 2013, the Company had 188,947 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $48.38 per share and 3,021,302 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $14.21 per share. The Company had a weighted average of 33,058 unearned restricted shares outstanding for the period ended December 31, 2013.
	Income Taxes
	In accordance with general accounting principles for income taxes, a deferred income tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred income tax assets unless, based upon available evidence, it is more likely than not the deferred income tax assets will be realized.
	Product Warranty Provisions
	The Company’s standard policy is to warrant all systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability (included in other accrued liabilities) as appropriate.
	Patent Costs
	Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain.
	Concentrations of Risk
	The majority of the Company’s cash, cash equivalents and investments are deposited with one major financial institution in the U.S. Deposits in this institution exceed the amount of insurance provided on such deposits.
	One customer, Biosense Webster Inc., as our distributor, accounted for $3,902,178,  $3,447,386, and $3,663,687, or 10%,  7% and 9%, of total net revenue for the years ended December 31, 2013, 2012, and 2011, respectively. No other single customer accounted for more than 10% of total revenue for the year ended December 31, 2013.
	Reclassifications
	Common stock and additional paid-in capital in the prior year’s financial statements have been reclassified to reflect the one-for-ten reverse stock split effected on July 10, 2012. Refer to Note 11 for additional discussion of the reverse stock split.
	Recently Issued Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (“ASU” or “Update”) 2013-02, “Comprehensive Income: Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income” which adds new disclosure requirements for items reclassified out of accumulated other comprehensive income (“AOCI”). The update requires that the Company present either in a single note or parenthetically on the face of the financial statements, the effect of significant amounts reclassified from each component of AOCI based on its source and the income statement line items affected by the reclassification. The guidance is effective for interim and annual reporting periods beginning on or after December 15, 2012. As the Company has no items of other comprehensive income, the Company is not required to report accumulated other comprehensive income.
	In December 2011, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2011-11, “Disclosures about Offsetting Assets and Liabilities.” The Update enhances the disclosure of offsetting assets and liabilities by requiring companies to disclose both the gross and net information about instruments and transactions eligible for offset as well as those subject to an agreement similar to master netting arrangements. This guidance is effective for the Company’s interim and annual periods beginning January 1, 2013. The adoption of this pronouncement did not have an impact on the financial statements.
	In June 2011, the FASB issued new accounting guidance related to the presentation of comprehensive income that increases comparability between U.S. GAAP and International Financial Reporting Standards (“IFRS”). This guidance eliminates the current option to report other comprehensive income (OCI) and its components in the statement of changes in stockholders’ equity. This guidance was effective for the Company’s interim and annual periods beginning January 1, 2012. As the Company has no items of other comprehensive income, the Company is not required to report comprehensive income or other comprehensive income.
	In May 2011, the FASB issued Accounting Standards Update No. 2011-04, “Fair Value Measurement: Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS.” The Update amends the guidance on fair value measurements to develop common requirements for measuring fair value and for disclosing information about fair value measurements in accordance with U.S. GAAP and IFRS. The Update does not require additional fair value measurements and is not intended to establish valuation standards or affect valuation practices outside of financial reporting. This guidance was effective during interim and annual periods beginning after December 15, 2011.  The adoption of this ASU did not have a material effect on our financial position or results of operations.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2013
Inventory [Abstract]	'
Inventory	'
	3. Inventory
	Inventory consists of the following:
		31-Dec-13	31-Dec-12
	Raw materials	$          3,141,111	$         3,303,053
	Work in process	364,779	65,546
	Finished goods	1,453,362	1,802,281
	Reserve for obsolescence	-80,213	-72,639
	Total inventory	$          4,879,039	$         5,098,241

Prepaid_Expenses_And_Other_Cur

Prepaid Expenses And Other Current Assets	12 Months Ended
	Dec. 31, 2013
Prepaid Expenses And Other Current Assets [Abstract]	'
Prepaid Expenses And Other Current Assets	'
	4. Prepaid Expenses and Other Current Assets
	Prepaid expenses and other current assets consist of the following:
		31-Dec-13	31-Dec-12
	Prepaid expenses	$        591,305	$       330,756
	Deferred cost of revenue	72,699	527,725
	Derivative asset	—	1,736
	Deferred financing costs	622,949	1,590,916
	Deposits	658,253	1,040,934
	Total prepaid expenses and other current assets	$     1,945,206	$    3,492,067
	Deferred cost of revenue represents the cost of systems for which risk of loss and or title has transferred from the Company but for which revenue has not been recognized.
	The derivative asset represents the fair value of a debt conversion feature that is part of the subordinated convertible debentures agreement.  Refer to Notes 9 and 12 for discussion of the debentures and fair value measurement, respectively.

Property_And_Equipment

Property And Equipment	12 Months Ended
	Dec. 31, 2013
Property And Equipment [Abstract]	'
Property And Equipment	'
	5. Property and Equipment
	Property and equipment consist of the following:
		December 31,	December 31,
		2013	2012
	Equipment	$          8,143,000	$    8,762,041
	Equipment held for lease	303,412	303,412
	Leasehold improvements	2,328,381	2,328,381
		10,774,793	11,393,834
	Less: Accumulated depreciation	-9,590,204	-9,251,911
	Net property and equipment	$          1,184,589	$    2,141,923

Intangible_Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2013
Intangible Assets [Abstract]	'
Intangible Assets	'
	6. Intangible Assets
	As of December 31, 2013 and 2012, the Company had total intangible assets of $3,665,000. Accumulated amortization at December 31, 2013 and 2012, was $1,985,514 and 1,685,680.  Amortization expense for the years 2013, 2012, and 2011 was $299,833 per year, as determined under the straight-line method. The estimated future amortization of intangible assets is $299,833 annually through July 2018, decreasing thereafter to $166,500 annually through May 2020.

Accrued_Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2013
Accrued Liabilities [Abstract]	'
Accrued Liabilities	'
	7. Accrued Liabilities
	Accrued liabilities consist of the following:
		December 31,	December 31,
		2013	2012
	Accrued salaries, bonus, and benefits	$     3,565,385	$    2,123,167
	Accrued rent	1,499,942	1,095,641
	Accrued warranties	501,212	653,473
	Accrued interest	498,058	469,049
	Accrued licenses and maintenance fees	302,384	323,901
	Accrued taxes	360,475	245,802
	Other	351,925	450,777
	Total accrued liabilities	$     7,079,381	$    5,361,810

Deferred_Revenue

Deferred Revenue	12 Months Ended
	Dec. 31, 2013
Deferred Revenue [Abstract]	'
Deferred Revenue	'
	8. Deferred Revenue
	Deferred revenue consists of the following:
		December 31,	December 31,
		2013	2012
	Product shipped, revenue deferred	$      1,368,007	$      3,206,641
	Customer deposits	421,544	558,227
	Deferred service and license fees	6,221,283	6,215,230
		8,010,834	9,980,098
	Less: Long-term deferred revenue	-491,080	-477,159
	Total current deferred revenue	$      7,519,754	$      9,502,939

LongTerm_Debt_And_Credit_Facil

Long-Term Debt And Credit Facilities	12 Months Ended
	Dec. 31, 2013
Long-Term Debt And Credit Facilities [Abstract]	'
Long-Term Debt And Credit Facilities	'
	9. Long-Term Debt and Credit Facilities
	Debt outstanding consists of the following:
		31-Dec-13				31-Dec-12
		Carrying		Estimated		Carrying	Estimated
		Amount		Fair Value		Amount	Fair Value
	Revolving line of credit, due March 2014	$                  -		$                  -		$         7,253,017	$         7,277,084
	Term note, due December 2013	—		—		4,000,000	4,000,000
	Healthcare Royalty Partners debt	18,531,211		18,531,211		16,248,075	16,248,075
	Subordinated convertible debentures	—		—		1,588,134	1,588,134
	Total debt	18,531,211		18,531,211		29,089,226	29,113,293
	Less current maturities	-49,733		-49,733		-12,264,490	-12,288,557
	Total long term debt	$ 18,481,478		$ 18,481,478		$       16,824,736	$       16,824,736
	Contractual principal maturities of debt at December 31, 2013 are as follows:
	2014		$	49,733
	2015			49,733
	2016			49,733
	2017			49,733
	2018			18,332,279
	2019 and Beyond			-
			$	18,531,211	-1
	(1) Future principal payments of Healthcare Royalty Partners debt based on estimated future royalties.
	In accordance with general accounting principles for fair value measurement, the Company’s debt and credit facilities were measured at fair value as of December 31, 2013 and December 31, 2012.  Long-term debt fair value estimates are based on estimated borrowing rates to discount the cash flows to their present value (Level 3).  The carrying amounts of the Subordinated Convertible Debentures are net of the respective unamortized debt discount as of December 31, 2012.
	The revolving line of credit and the Company’s obligations with Healthcare Royalty Partners II, L.P. (collectively, the “Credit Agreements”) are secured by substantially all of the Company’s assets. The Company is also required under the Credit Agreements to maintain its primary operating account and the majority of its cash and investment balances in accounts with the primary lender.
	Revolving line of credit
	In November 2010, the Company received from stockholders, who at the time were affiliates of two members of our board of directors (“the Lenders”), an extension of their commitment to provide $10 million in either direct loans to the Company or loan guarantees to the Company’s primary bank lender through the earlier of March 31, 2012 or the date the Company receives $30 million of third party, non-bank financing, coincidental with the proposed maturity of the bank line of credit, as amended. The Company granted to the Lenders warrants to purchase 80,000 shares in exchange for their extension. The warrants are exercisable at $40.15 per share, beginning on March 1, 2011 and expiring on February 28, 2016. The fair value of these warrants of $1,747,392, calculated using the Black-Scholes method, was deferred and amortized to interest expense ratably. As the previous guarantee was no longer in effect, the Company expensed in 2010 the entire balance on the warrants issued to the Lenders in October 2009.
	In December 2010, the Company further amended its agreement with its primary lender to extend the maturity of the current working capital line of credit from March 31, 2011 to March 31, 2012, retaining the $30 million total availability under the line per the 2009 amendment. The revised agreement retained the $10 million sublimit for borrowings supported by guarantees from the Lenders. Under the revised facility the Company was required to maintain a minimum “tangible net worth” and liquidity ratio as defined in the agreement. Interest on the facility accrued at the rate of prime plus 0.5% subject to a floor of 6% for the amount under guarantee and prime plus 1.75% subject to a floor of 7% for the remaining amounts.
	In September 2011, the Company amended its agreement with its primary lender.  The amendment reduced the availability amount of all credit extensions, other than the term loan, from $30 million to $20 million, and modified the interest rate applicable to the term loan from the lender’s prime rate plus 3.5% to the bank’s prime rate plus 5.5%.
	On November 30, 2011, the Company entered into a Second Amended and Restated Loan and Security Agreement with its primary lender (“Amended Loan Agreement”). Under the Amended Loan Agreement, the Company agreed to revised tangible net worth and liquidity ratio covenants. Further, certain intellectual property assets of the Company were added to the collateral which secures repayment of the loan. Finally, the Amended Loan Agreement permits the Company to repay Healthcare Royalty Partners II, L.P. (“Healthcare Royalty Partners”), formerly “Cowen Healthcare Royalty Partners II, L.P.”, with the royalties due to the Company under the Biosense Agreement (the "Biosense Agreement"), as described below.
	On March 30, 2012, the Company amended its agreement with its primary lender.  The amendment extended the maturity date of the working capital line of credit from March 31, 2012 to April 30, 2012 and reduced the Company’s borrowing availability by $3,333,333.  The Company also received from the Lenders an extension of their commitment to provide $10 million in loan guarantees until April 30, 2012.  As a result of this extension, the Company issued the Lenders warrants to purchase 75,735 shares of common stock at $6.60 per share.
	On May 1, 2012, the Company and its primary lender entered into an agreement in which the lender extended the maturity of the revolving line of credit from April 30, 2012 to May 15, 2012.  The Company and the Lenders also agreed to amend their agreement to extend the $10 million loan guarantee through May 15, 2012.  The Company granted warrants to purchase an aggregate of 60,976 shares of common stock at $4.10 per share in exchange for the extension of the guarantee.
	On May 10, 2012, upon closing of financing transactions for gross proceeds of $18.5 million, the Company entered into the Third Loan Modification Agreement with its primary lender.  The amendment extended the revolving credit facility maturity to March 31, 2013 and revised the financial covenants.  Additionally, the revolving line of credit was decreased from $20 million to $13 million.  The reduction was as a result of the pay down of $7 million of the guarantees provided by the Lenders.  In addition the Company and the Lenders agreed to decrease the $10 million guarantee to $3 million and to further extend the loan guarantee through March 31, 2013. The Company granted warrants to purchase an aggregate of 234,305 shares of common stock at $3.361 per share in exchange for the extension of the guarantee.
	On March 29, 2013, the Company amended its agreement with its primary lender. The amendment extended the maturity date of the working capital line of credit from March 31, 2013 to June 30, 2013. The Company and the Lenders also agreed to extend until June 30, 2013 the $3 million guarantee.  As a result of this extension, the Company issued the Lenders warrants to purchase 113,636 shares of common stock at $1.98 per share.
	On June 28, 2013, the Company amended its agreement with its primary lender. The amendment extended the maturity date of the working capital line of credit from June 30, 2013 to July 31, 2013, and decreased the amount of available advances from $13 million to $6 million. In addition, the Bank waived the testing of the tangible net worth and liquidity ratio financial covenants under the Amended Loan Agreement for the period ended June 30, 2013. The Company and the Lenders also agreed to extend until July 31, 2013 the $3 million guarantee.  As a result of this extension, the Company issued the Lenders warrants to purchase 48,387 shares of common stock at $1.55 per share.
	On July 31, 2013, the Company amended its agreement with its primary lender. The amendment extended the maturity date of the working capital line of credit from July 31, 2013 to August 31, 2013.  In addition, the Bank waived the testing of the liquidity ratio financial covenant under the Amended Loan Agreement for the period ended July 31, 2013. The Company and the Lenders also agreed to extend until August 31, 2013 the $3 million guarantee.  As a result of this extension, the Company issued the Lenders warrants to purchase 14,313 shares of common stock at $5.24 per share.
	On August 30, 2013, the Company amended its agreement with its primary lender. The amendment extended the maturity date of the working capital line of credit from August 31, 2013 to March 31, 2014. In addition, the Company and the Bank agreed to a reduction in the revolving credit line from $6.0 million to $3.0 million, the elimination of the $3.0 million sublimit guaranteed by the Lenders, and release of the guarantees by the Lenders in favor of the Bank. The amendment eliminated the prepayment premium for the prepayment of the term loan and modified the financial covenants to (a) eliminate the minimum tangible net worth covenant, (b) substitute in lieu thereof an EBITDA test, requiring the Company to maintain a minimum EBITDA of no less than (no worse than) (i) negative $4.0 million for the trailing three-month period ending September 30, 2013 and (ii) negative $3.0 million for the trailing three-month period ending December 31, 2013, in each case tested quarterly on a trailing three month basis, and (c) revise the liquidity ratio covenant to require the Company to maintain a liquidity ratio of greater than 2:1, excluding certain short term advances from the calculation.
	As of December 31, 2013, the Company had no outstanding debt under the revolving line of credit.  Draws on the line of credit are made based on the borrowing capacity one week in arrears.  As of December 31, 2013, the Company had a borrowing capacity of $3.0 million based on the Company’s collateralized assets.  As such, the Company had ability to borrow $3.0 million under the revolving line of credit at December 31, 2013.
	Term note
	Under the 2010 amendment to the loan agreement, the Company entered into a $10 million term loan maturing on December 31, 2013, with $2 million of principal due in 2011 and $4 million of principal due in each of 2012 and 2013. Interest on the term loan accrued at the rate of prime plus 3.5%. Under this agreement, the Company provided its primary lender with warrants to purchase 11,111 shares of common stock. The warrants are exercisable at $36.00 per share, beginning on December 17, 2010 and expiring on December 17, 2015. The fair value of these warrants of $228,332, calculated using the Black-Scholes method, was deferred and amortized to interest expense ratably over the life of the term loan. The term note was paid in full in September 2013.
	Healthcare Royalty Partners Debt
	In November 2011, the Company entered into a loan agreement with Healthcare Royalty Partners II, L.P. (formerly “Cowen Healthcare Royalty Partners II, L.P.”). Under the agreement the Company borrowed from Healthcare Royalty Partners $15 million. The Company was permitted to borrow up to an additional $5 million in the aggregate based on the achievement by the Company of certain milestones related to Niobe system sales in 2012. On August 8, 2012, the Company borrowed an additional $2.5 million based upon achievement of a milestone related to Niobe system sales for the nine months ended June 30, 2012. On January 31, 2013, the Company borrowed an additional $2.5 million based upon achievement of a milestone related to Niobe system sales for the twelve months ended December 31, 2012.  The loan will be repaid through, and secured by, royalties payable to the Company under its Development, Alliance and Supply Agreement with Biosense Webster, Inc. The Biosense Agreement relates to the development and distribution of magnetically enabled catheters used with Stereotaxis' Niobe system in cardiac ablation procedures. Under the terms of the Agreement, Healthcare Royalty Partners will be entitled to receive 100% of all royalties due to the Company under the Biosense Agreement until the loan is repaid.  The loan is a full recourse loan, matures on December 31, 2018, and bears interest at an annual rate of 16% payable quarterly with royalties received under the Biosense Agreement. If the payments received by the Company under the Biosense Agreement are insufficient to pay all amounts of interest due on the loan, then such deficiency will increase the outstanding principal amount on the loan. After the loan obligation is repaid, the royalties under the Biosense Agreement will again be paid to the Company. The loan is also secured by certain assets and intellectual property of the Company. The Agreement also contains customary affirmative and negative covenants. The use of payments due to the Company under the Biosense Agreement was approved by our primary lender under the Amended Loans Agreement described above.
	Subordinated Convertible Debentures
	In May 2012, the Company entered into a securities purchase agreement with certain institutional investors whereby the Company agreed to sell an aggregate of approximately $8.5 million in aggregate principal amount of unsecured, subordinated, convertible debentures (the “Debentures”), which became convertible into shares of the Company’s common stock at a conversion price of $3.361 per share (or approximately 2.5 million shares in the aggregate), on July 10, 2012, the date that the Company received shareholder approval for the transaction.  The purchasers of the Debentures also received warrants, which were scheduled to expire in November 2018, to purchase an aggregate of approximately 2.5 million shares of the Company’s common stock at an exercise price of $3.361 per share.  The Debentures bore interest at 8% per year and were scheduled to mature on May 7, 2014.  In addition, the Company had the ability to issue shares of its common stock in lieu of cash interest payments under certain circumstances, and following the registration of the shares for resale, the Company issued shares in lieu of cash interest payments
	The Company recorded the Debentures on the balance sheet net of the debt discount of $7.6 million.  The debt discount was due to warrants issued in conjunction with the Debentures and the debt conversion features.  Upon issuance of the Debentures, the fair value of the warrants and derivative liability were $4.1 million and $3.5 million, respectively.  The debt discount was amortized over the life of the loan using the effective interest method and the warrants and derivative liability were recorded at fair value on each reporting period.  Refer to Note 12 for additional discussion of the fair value of the warrants and conversion features.
	On August 7, 2013, holders of Convert Warrants exercised all of their Convert Warrants for an aggregate of approximately 2.5 million shares of our common stock, resulting in cash proceeds of approximately $8.5 million. In addition, holders of all of the Debentures exchanged the balance of their unconverted Debentures for an aggregate of approximately 2.7 million shares of the Company’s common stock and additional warrants (the “Exchange Warrants”) to purchase approximately 2.5 million shares, having an exercise price of $3.361 per share. On August 8, 2013, certain former holders of the Debentures exercised Exchange Warrants to purchase an aggregate of 1.4 million shares of common stock in cashless net exercises as provided for in the Exchange Warrants, which resulted in the issuance to such funds of an aggregate of 0.8 million shares of common stock but no net proceeds to the Company. The Company is relying on the exemption from registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended, based on representations to the Company made by the warrant holders. Refer to Note 11 for discussion of total outstanding warrants.
	The mark-to-market expense associated with the adjustment of warrants and convertible debt features in connection with the third quarter capital transactions are included in other expense for the year ended December 31, 2013.  The write-off of the unamortized debt discount of $5.4 million is included in interest expense for the year ended December 31, 2013.
	Biosense Webster Advance
	In July 2008, the Company and Biosense Webster entered into an amendment to their existing agreements relating to the development and sale of catheters. Pursuant to the amendment, Biosense Webster agreed to pay to the Company $10.0 million as an advance on royalty amounts that were owed at the time the amendment was executed or would be owed in the future by Biosense Webster to the Company pursuant to the royalty provisions of one of the existing agreements. The Company and Biosense Webster also agreed that an aggregate of up to $8.0 million of certain agreed upon research and development expenses that were owed at the time the amendment was executed or may be owed in the future by the Company to Biosense Webster pursuant to the existing agreement would be deferred and would be due, together with any unrecouped portion of the $10.0 million royalty advance, no later than December 31, 2011. Interest on the outstanding and unrecouped amounts of the royalty advance and deferred research and development expenses accrued at an interest rate of the prime rate plus 0.75%. Outstanding royalty advances and deferred research and development expenses and accrued interest thereon were recouped by Biosense Webster by deductions from royalty amounts otherwise owed to the Company from Biosense Webster pursuant to the existing agreement. Approximately $18.0 million had been advanced by Biosense Webster to the Company pursuant to the amendment. As of December 31, 2011, these amounts plus interest accrued thereon had been repaid in full, in accordance with the agreement. The Company recorded research and development expenses of $1.1 million and disposables, service and accessories revenue of $3.6 million for the year ended December 31, 2011, related to this agreement.

Lease_Obligations

Lease Obligations	12 Months Ended
	Dec. 31, 2013
Lease Obligations [Abstract]	'
Lease Obligations	'
	10. Lease Obligations
	The Company leases its facilities under operating leases. For the years ended December 31, 2013, 2012, and 2011 rent expense was $1,925,813, $1,697,153, and $1,711,647, respectively.
	In January 2006, the Company moved its primary operations into new facilities. The facility is subject to a lease which expires in 2018. Under the terms of the lease, the Company has options to renew for up to three additional years. The lease contains an escalating rent provision which the Company has straight-lined over the term of the lease.
	In the third quarter of 2013, the Company modified the existing lease agreement to terminate approximately 13,000 square feet of unimproved space. The costs associated with the termination were accrued as a rent liability.
	The future minimum lease payments under non-cancelable leases as of December 31, 2013 are as follows:
			Operating
	Year		Lease
	2014	$	1,593,756
	2015		1,562,353
	2016		1,930,829
	2017		1,981,467
	2018		2,008,832
	Total minimum lease payments	$	9,077,237

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity [Abstract]	'
Stockholders' Equity	'
	11. Stockholders’ Equity
	Listing Transfer to NASDAQ Capital Market
	On August 15, 2013, the NASDAQ Listing Qualifications Panel (the “Panel”) granted approval of the Company’s request to transfer its listing to The NASDAQ Capital Market from The NASDAQ Global Market. The Company’s securities began trading on the NASDAQ Capital Market effective August 19, 2013.
	Reverse Stock Split
	On July 10, 2012, the Company filed a Certificate of Amendment to our Amended and Restated Certificate of Incorporation to implement a one-for-ten reverse split of our common stock (the “Reverse Stock Split”).  The ratio for the Reverse Stock Split was determined by our Board of Directors pursuant to the approval of the stockholders at the Company’s special meeting of stockholders held on July 10, 2012, authorizing the Board to effect a reverse stock split within a range of one-for-four to one-for-ten shares of the Company’s common stock.  The Reverse Stock Split was effective as of July 10, 2012, and the Company’s common stock began trading on the NASDAQ Global Market on a post-split basis on July 11, 2012.
	As a result of the Reverse Stock Split, each ten shares of the Company’s issued and outstanding common stock were automatically combined and converted into one issued and outstanding share of common stock.  The Reverse Stock Split affected all issued and outstanding shares of the Company’s common stock, as well as common stock underlying stock options, stock appreciation rights, restricted stock, restricted stock units, warrants and convertible debentures outstanding immediately prior to the effectiveness of the Reverse Stock Split.  The Reverse Stock Split reduced the number of shares of the Company’s common stock outstanding from approximately 78 million to 7.8 million at the time of the Reverse Stock Split.  In addition, the Amendment increased the number of authorized shares of the Company’s common stock from 100 million to 300 million.  The Reverse Stock Split did not alter the par value of common stock, which remained $0.001 per share, or modify any voting rights or other terms of the Company’s common stock.  Unless otherwise indicated, all information set forth herein gives effect to such Reverse Stock Split.
	Public Offerings of Common Stock
	In May 2012, the Company entered into a Stock and Warrant Purchase Agreement with certain institutional investors whereby it agreed to sell an aggregate of approximately 2.17 million shares of the Company's common stock (the “PIPE Common Stock”) at a price of $3.361 per share, together with six-year warrants at a price of $1.25 per share to purchase an aggregate of approximately 2.17 million shares of common stock having an exercise price of $3.361 per share (the “PIPE Warrants”). Each purchaser received a PIPE Warrant to purchase one share of common stock for every share of PIPE Common Stock purchased. Net proceeds from the sale of the securities were approximately $9.1 million, after placement agent fees and other offering expenses.  The Company used the funds to repay $7 million of the revolving credit facility guaranteed by the Lenders and plans to use the balance for working capital and general corporate purposes.
	On August 7, 2013, venture funds affiliated with Sanderling Ventures received an aggregate of 183,478 shares of common stock based upon the cashless exercise of warrants to purchase an aggregate of 262,450 shares of common stock. These warrants were comprised of 75,758 warrants with an exercise price of $1.98 per share, 156,204 warrants with an exercise price of $3.361 per share and 30,488 warrants with an exercise price of $4.10 per share. The warrants were issued by the Company in private placements in 2012 and 2013 in connection with the extension of previously disclosed guarantees.
	On August 13, 2013, venture funds affiliated with Sanderling Ventures exercised PIPE Warrants to purchase an aggregate of 650,619 shares of common stock in a cashless net exercise as provided for in the PIPE Warrants, which resulted in the issuance to such funds of an aggregate of 308,194 shares of common stock. As a result, there were no net proceeds to the Company.
	On August 16, 2013, certain affiliates of Franklin Templeton exercised PIPE Warrants to purchase an aggregate of 650,618 shares of common stock for cash. The Company received an aggregate of $2,186,727 gross proceeds from the sale.
	On August 16, 2013, Alafi Capital Company exercised PIPE Warrants to purchase an aggregate of 261,241 shares of common stock for cash. The Company received an aggregate of $878,031 gross proceeds from the sale. Refer to Note 9 for the discussion of warrants issued in conjunction with debt offerings.
	On November 27, 2013, the Company announced the results of its previously announced offering of subscription rights to purchase shares of its common stock, par value $0.001 per share. Pursuant to the rights offering, subscription rights to purchase approximately 3.4 million shares of common stock were exercised, resulting in gross proceeds to Stereotaxis of approximately $10.2 million.
	The holders of common stock are entitled one vote for each share held and to receive dividends whenever funds are legally available and when declared by the Board of Directors subject to the prior rights of holders of all classes of stock having priority rights as dividends and the conditions of the our Revolving Credit Agreement. No dividends have been declared or paid as of December 31, 2013.
	The Company has reserved shares of common stock for the exercise of warrants, the issuance of options granted under the Company’s stock option plan and its stock purchase plan as follows:
			December 31,		December 31,
			2013		2012
	Warrants		3,021,302		6,099,476
	Stock award plans		1,032,462		131,464
			4,053,764		6,230,940
	Stock Award Plans
	The Company has various stock plans that permit the Company to provide incentives to employees and directors of the Company in the form of equity compensation.  In August 2012, the Board of Directors adopted a stock incentive plan (the 2012 Stock Incentive Plan) which was subsequently approved by the Company’s stockholders. This plan replaces the 2002 Stock Incentive Plan which expired on March 25, 2012.
	The 2012 Stock Incentive Plan allows for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted shares and restricted share units to employees, directors, and consultants. Options granted under the 2012 Stock Incentive Plan expire no later than ten years from the date of grant. The exercise price of each incentive stock option shall not be less than 100% of the fair value of the stock subject to the option on the date the option is granted. The vesting provisions of individual options may vary, but incentive stock options generally vest 25% on the first anniversary of each grant and 1/48 per month over the next three years. Stock appreciation rights are rights to acquire a calculated number of shares of the Company’s common stock upon exercise of the rights. The number of shares to be issued is calculated as the difference between the exercise price of the right and the aggregate market value of the underlying shares on the exercise date divided by the market value as of the exercise date. Stock appreciation rights granted under the 2012 Stock Incentive Plan generally vest 25% on the first anniversary of such grant and 1/48 per month over the next three years and expire no later than ten years from the date of grant. The Company generally issues new shares upon the exercise of stock options and stock appreciation rights.
	Restricted share grants are either time-based or performance-based. Time-based restricted shares generally cliff vest three years after grant. Performance-based restricted shares vest upon the achievement of performance objectives which are determined by the Company’s Board of Directors.
	Restricted stock unit grants are time-based and generally vest over a period of four years. Options granted to non-employee directors expire no later than ten years from the date of grant. The exercise price of options to non-employee directors shall not be less than 100% of the fair value of the stock subject to the option on the date the option is granted. Initial grants of options to new directors generally vest over a two year period. Annual grants to directors generally vest upon the earlier of one year or the next stockholder meeting.
	A summary of the option and stock appreciation rights activity for the year ended December 31, 2013 is as follows:
		Number of Options/SARs		Range of Exercise Price		Weighted Average Exercise Price per Share
	Outstanding, December 31, 2012	373,899		$1.63 - $116.40		$
						43.90
	Granted	-		$0.00 - $0.00		-
	Exercised	-145		$6.80 - $6.80		$
						6.80
	Forfeited	-184,807		$1.69 - $68.60		$
						39.34
	Outstanding, December 31, 2013	188,947		$1.63 - $116.40		$
						48.38
	As of December 31, 2013, the weighted average remaining contractual life of the options and stock appreciation rights outstanding was 3.88 years. Of the 188,947 options and stock appreciation rights that were outstanding as of December 31, 2013, 169,199 were vested and exercisable with a weighted average exercise price of $50.05 per share and a weighted average remaining term of 3.69 years.
	A summary of the options and stock appreciation rights outstanding by range of exercise price is as follows:
			Year Ended December 31, 2013
										Number of		Weighted
						Weighted		Weighted		Options		Average Exercise
			Options			Average		Average		Currently		Price Per Vested
	Range of Exercise Prices		Outstanding			Remaining Life		Exercise Price		Exercisable		Share
	$0.00 - $20.00			3,975			6.15 years	$	6.04		2,321	$	5.41
	$20.01 - $40.00			92,356			5.32 years	$	35.13		77,390	$	35.08
	$40.01 - $60.00			59,308			2.72 years	$	46.69		56,180	$	46.93
	$60.01 - $90.00			13,408			0.85 years	$	74.04		13,408	$	74.04
	$90.01 - $120.00			19,900			2.21 years	$	106.11		19,900	$	106.11
				188,947			3.88 years	$	48.38		169,199	$	50.05
	The intrinsic value of options and stock appreciation rights is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock for the 1,625 options and stock appreciation rights that were in-the-money at December 31, 2013. The intrinsic value of the options and stock appreciation rights outstanding at December 31, 2013 and the intrinsic value of fully vested options and stock appreciation rights outstanding at December 31, 2013 were less than $0.1 million based on a closing share price of $3.62 on December 31, 2013.   During the year ended December 31, 2013, the aggregate intrinsic value of options and stock appreciation rights exercised under the Company’s stock option plans was less than $0.1 million. No options or SARS were granted during the year ended December 31, 2013.
	During the year ended December 31, 2013 the Company realized less than $0.1 million from the exercise of stock options and stock appreciation rights.  The Company realized $0 and less than $0.1 million from the exercise of stock options and stock appreciation rights during 2012 and 2011, respectively.
	A summary of the restricted share grant activity for the year ended December 31, 2013 is as follows:
		Number of Shares		Weighted Average Grant Date Fair Value per Share
	Outstanding, December 31, 2012	68,543		$
				20.62
	Granted	-		-
	Vested	-33		$
				33.80
	Forfeited	-61,910		$
				19.06
	Outstanding, December 31, 2013	6,600		$
				35.20
	A summary of the restricted stock unit activity for the year ended December 31, 2013 is as follows:
	Number of Restricted Stock Units		Weighted Average Grant Date Fair Value per Unit
Outstanding, December 31, 2012	529,312		$
			2.64
Granted	449,000		$
			2.20
Vested	-211,615		$
			3.82
Forfeited	-177,938		$
			2.09
Outstanding, December 31, 2013	588,759		$
			2.05
A summary of the restricted shares outstanding as of December 31, 2013 is as follows:
	Number of Shares
Time based restricted shares	6,600
Performance based restricted shares	-
Outstanding, December 31, 2013	6,600
The intrinsic value of restricted shares and restricted stock units outstanding at December 31, 2013 was less than $0.1 million and $2.1 million, respectively, based on a closing share price of $3.62 as of December 31, 2013. During the year ended December 31, 2013, the aggregate intrinsic value of restricted shares and restricted stock units vested was approximately $0 and $0.3 million, respectively, determined at the date of vesting.
During the year ended December 31, 2013, the Company determined that it was not probable that the performance conditions related to certain of its outstanding restricted share awards would be achieved and accordingly, recorded approximately $(0.2) million as a cumulative catch-up adjustment resulting in a reduction of share based compensation. During the second quarter of 2013, the Company made an adjustment to its forfeiture rate based on historical information, which resulted in a reduction of share-based compensation of $(0.5) million for the year ended December 31, 2013.
As of December 31, 2013, the total compensation cost related to options, stock appreciation rights and non-vested stock granted to employees under the Company’s stock award plans but not yet recognized was approximately $1.3 million, net of estimated forfeitures of approximately $1.2 million. This cost will be amortized over a period of up to four years on a straight-line basis over the underlying estimated service periods and will be adjusted for subsequent changes in estimated forfeitures.
2009 Employee Stock Purchase Plan
In 2009, the Company adopted its 2009 Employee Stock Purchase Plan and reserved 25,000 shares of common stock for issuance pursuant to the plan. The Company offered employees the opportunity to participate in the plan beginning July 1, 2009 with an initial purchase date of September 30, 2009. Eligible employees had the opportunity to participate in a new purchase period every 3 months. Under the terms of the plan, employees could purchase up to 15% of their compensation of the Company’s common stock, subject to an annual maximum of $25,000, at 95% of the fair market value of the stock at the end of the purchase period, subject to certain plan limitations.  The plan was suspended in 2012 and no shares were available for issuance as of December 31, 2013.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Fair Value Measurements [Abstract]	'
Fair Value Measurements	'
	12. Fair Value Measurements
	The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). The three levels of the fair value hierarchy are described below:
	Level 1: Values are based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
	Level 2: Values are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or other model-based valuation techniques for which all significant assumptions are observable in the market.
	Level 3: Values are generated from model-based techniques that use significant assumptions not observable in the market.
	The following table sets forth the Company’s assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy.  As required by the Fair Value Measurements and Disclosures topic of the Accounting Standards Codification, assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.
		Fair Value Measurement Using
		Total			Quoted Prices in		Significant		Significant
					Active Markets		Other		Unobservable
					for Identical		Observable		Inputs
					Instruments		Inputs		(Level 3)
					(Level 1)		(Level 2)
	Assets at December 31, 2013:
	Cash equivalents	$	11,995,481		11,995,481		—		—
	Total assets at fair value	$	11,995,481		11,995,481		—		—
	Liabilities at December 31, 2013:
	Warrants issued December 29, 2008	$	16,863		—		—		16,863
	Warrants issued May 10, 2012		1,915,753		—		—		1,915,753
	Warrants issued August 2013		3,712,010						3,712,010
	Total liabilities at fair value:	$	5,644,626		—		—		5,644,626
	Assets at December 31, 2012:
	Cash equivalents	$	256,702		256,702		—		—
	Derivative asset		1,736		—		—		1,736
	Total assets at fair value	$	258,438		256,702		—		1,736
	Liabilities at December 31, 2012:
	Warrants issued December 29, 2008	$	71,581		—		—		71,581
	Warrants issued May 10, 2012		2,347,902		—		—		2,347,902
	Derivative liability		548,865		—		—		548,865
	Total liabilities at fair value:	$	2,968,348		—		—		2,968,348
	Level 1
	The Company’s financial assets consist of cash equivalents invested in money market funds in the amount of $11,995,481 and $256,702 at December 31, 2013 and December 31, 2012, respectively. These assets are classified as Level 1 as described above and total interest income recorded for these investments was insignificant during both the years ended December 31, 2013 and December 31, 2012. There were no transfers in or out of Level 1 during the year ended December 31, 2013.
	Level 2
	The Company does not have any financial assets or liabilities classified as Level 2.
	Level 3
	In conjunction with its December 29, 2008 registered direct offering, the Company issued warrants to purchase 179,241 shares of the Company’s common stock that contained a provision that required a reduction of the exercise price if certain equity events occurred. Under the provisions of general accounting principles for derivatives and hedging activities and determining whether an instrument (or embedded feature) is indexed to an entity’s own stock, such a reset provision does not meet the exemptions for equity classification and as such, the Company accounts for these warrants as derivative instruments. The calculated fair value of the warrants is classified as a liability and is periodically remeasured with any changes in value recognized in “Other income (expense)” in the Statement of Operations. General accounting principles for determining whether an instrument (or embedded feature) is indexed to an entity’s own stock became effective for the Company as of January 1, 2009. Accordingly, the fair value of the warrants as of that date was reclassified from stockholders’ equity into current liabilities.
	In accordance with general accounting principles for fair value measurement, the Company’s warrants in the amount of $16,863 were measured at fair value on a recurring basis as of December 31, 2013 and were valued using Level 3 valuation inputs. A Black-Scholes model was used to value the Company’s warrants at December 31, 2013 using the following assumptions: 1) dividend yield of 0%; 2) volatility of 112.66%; 3) risk-free interest rate of 0.78%; and 4) expected life of 0.5 years.
	In the Company’s May 2012 financing transaction, the Company issued subordinated convertible debentures and warrants.  The optional conversion feature of the subordinated convertible debentures is classified as a derivative liability within “Warrants and derivative liabilities” on the Company’s balance sheet.  The warrants issued in conjunction with the Debentures and PIPE are also considered a liability.  Due to the provisions included in the warrant agreements, the warrants do not meet the exemptions for equity classification and as such, the Company accounts for these warrants as derivative instruments. The warrants and derivative liability were periodically remeasured with any changes in value recognized in “Other income (expense)” in the Statement of Operations.
	Per the terms of the Debentures agreement, the Company had the ability to require each holder to convert up to 50% of the Debentures if the common stock closed above $15.00, or 100% of the Debentures if the common stock closed above $20.00 (in each case, as adjusted for stock splits, recapitalizations and similar events) during a 20 consecutive trading day period and the resale registration statement had been declared effective by the SEC and was available for the issuance of the common stock upon conversion of the Debentures. In the event of any forced conversion by the Company, the minimum amount that the Company could force the holders to convert was $2.5 million of Debentures in the aggregate. This mandatory redemption clause was classified as a derivative asset within “Prepaid and other current assets” on the Company’s balance sheet. The derivative asset was periodically remeasured with any changes in value recognized in “Other income (expense)” in the Statement of Operations.
	A Monte-Carlo simulation was used to value the derivative asset, liabilities and warrants upon issuance on May 10, 2012 using the following assumptions: 1) volatility of 80%; 2) risk-free interest rate of 1.035%; and 3) a closing stock price of $3.413. Based on the discussion of the Debentures in Note 11, the Debentures along with their derivative liability and asset, and related warrants were extinguished in the third quarter of 2013.
	The initial valuation of Exchange warrants were valued as of August 7, 2013 using the following assumptions: 1) volatility of 111%; 2) risk-free interest rate of 1.46%; and 3) a closing stock price of $8.69.
	In accordance with general accounting principles for fair value measurement, the remaining PIPE and Exchange warrants were revalued as of December 31, 2013 using the following assumptions: 1) volatility of 142.28%; 2) risk-free interest rate of 1.75%; and 3) a closing stock price of $3.62.
	The significant unobservable input used in the fair value measurement of the Company’s warrants is volatility. Significant increases (decreases) in the volatility in isolation would result in a significantly higher (lower) asset and liability fair value measurements.
	The following table sets forth a summary of changes in the fair value of the Company’s Level 3 financial asset and liabilities for the year ended December 31, 2013:
		Derivative Asset		Total Assets		Warrants issued December 29, 2008		Warrants issued May 2012		Warrants issued August 2013	Derivative Liability	Total Liabilities
	Balance at beginning of period	$       1,736		$       1,736		$                71,581		$           2,347,902		$                    -	$      548,865	$     2,968,348
	Issues	-		-		-				19,358,108		19,358,108
	Settlements	-		-		-		-18,780,167		-10,535,592	-12,828,650	-42,144,409
	Revaluation	-1,736		-1,736		-54,718		18,348,018		-5,110,506	12,279,785	25,462,579
	Balance at end of period	$               -		$               -		$                16,863		$           1,915,753		$     3,712,010	$                  -	$     5,644,626
	The Company currently does not have derivative instruments to manage its exposure to currency fluctuations or other business risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. All derivative financial instruments are recognized in the balance sheet at fair value.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Taxes [Abstract]	'
Income Taxes	'
	13. Income Taxes
	The provision for income taxes consists of the following:
		Year Ended December 31,
		2013		2012		2011
	Deferred:
	Federal	$	-93,078,760	$	4,586,506	$	11,367,771
	State and local		-6,128,198		493,946		1,437,062
			-99,206,958		5,080,452		12,804,833
	Valuation allowance		99,206,958		-5,080,452		-12,804,833
		$	—	$	—	$	—
	The provision for income taxes varies from the amount determined by applying the U.S. federal statutory rate to income before income taxes as a result of the following:
		Year Ended December 31,
		2013		2012		2011
	U.S. statutory income tax rate	34.0	%	34	%	34	%
	State and local taxes, net of federal tax benefit	-8.9	%	5.2	%	4.5	%
	Permanent differences between book and tax and other	-169.4	%	14.4	%	1.5	%
	Valuation allowance	144.3	%	-53.6	%	-40	%
	Effective income tax rate	—	%	—	%	—	%
	Included in permanent differences between book and tax and other in the above table are the impacts of the Section 382 limitation (discussed below) and the non-deductible mark-to-market activity associated with convertible debt and warrants as well as permanent differences such as nondeductible meals and entertainment.
	The components of the deferred tax asset are as follows:
		December 31,
		2013		2012
	Current accruals	$	1,998,086	$	1,753,064
	Depreciation and amortization		2,566,979		2,676,884
	Deferred compensation		5,421,688		5,332,415
	Net operating loss carryovers		28,045,831		127,477,179
	Deferred tax assets		38,032,584		137,239,542
	Valuation allowance		-38,032,584		-137,239,542
	Net deferred tax assets	$	—	$	—
	Under Section 382 and 383 of the Internal Revenue Code of 1986, as amended, or the “Code”, if a corporation undergoes an “ownership change,” the corporation’s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research tax credits, to offset its post-change income may be limited. In general, an “ownership change” will occur if there is a cumulative change in our ownership by “5-percent shareholders” that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. Following significant ownership changes during 2013, the Company initiated a review of the availability of its U.S. net operating loss carryforwards.  As a result of this review, it was determined that a large portion of the Company’s net operating loss carryovers would expire unused due to the limitation under IRC Section 382.  The Company reduced the net operating loss carryover and corresponding valuation allowance as a result of these limitations as reflected in the net operating loss carryovers in the table above.  The remaining net operating loss carryforwards following the ownership change have been assigned a full valuation allowance against all deferred tax assets.
	In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers projected future taxable income and tax planning strategies in making this assessment. Based upon the level of historical taxable losses, and projections for future periods over which the deferred tax assets are deductible, the Company determined that a 100% valuation allowance of deferred tax assets was appropriate. The valuation allowance for deferred tax assets includes amounts for which subsequently recognized tax benefits will be applied directly to contributed capital.
	Based on the results of the review, discussed above, as of December 31, 2013, we had federal net operating loss carryforwards of approximately $75.8 million. The federal net operating loss carryforwards will expire between 2018 and 2033. As of December 31, 2013, we had state net operating loss carryforwards of approximately $2.3 million which will expire at various dates between 2014 and 2032 if not utilized.
	The Company files income tax returns in the U.S. federal jurisdiction and various state and local jurisdictions. As the Company has a federal net operating loss carryforward from the year ended December 31, 1994 forward, all tax years from 1994 forward are subject to examination. As states have varying carryforward periods, and the Company has recently entered into additional states, the states are generally subject to examination for the previous 10 years or less.
	The Company recognizes interest accrued, if any, net of tax and penalties, related to unrecognized tax benefits as components of income tax provision as applicable. As of December 31, 2013 accrued interest and penalties were not material.
	At December 31, 2013 and 2012, the Company had approximately $0.2 million in reserves for uncertain tax positions.

Net_Loss_Per_Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2013
Net loss per common share:	'
Net Loss Per Share	'
	14. Net Loss per Share
	The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the basic and diluted earnings per share calculations:
			2013			2012		2011
	Numerator:
	Numerator for basic EPS		$	-68,757,589		$	-9,238,427	$	-32,031,175
	Effect of dilutive securities
	Numerator for diluted EPS		$	-68,757,589		$	-9,238,427	$	-32,031,175
	Denominator:
	Denominator for basic EPS—weighted average shares			11,554,566			6,944,928		5,482,627
	Effect of dilutive securities
	Denominator for diluted EPS			11,554,566			6,944,928		5,482,627
	Basic EPS		$	-5.95		$	-1.33	$	-5.84
	Diluted EPS		$	-5.95		$	-1.33	$	-5.84
	The following table sets forth the number of common shares that were excluded from the computation of diluted earnings per share because their inclusion would have been anti-dilutive as follows:
		December 31,
			2013		2012		2011
	Shares outstanding
	Restricted shares		6,600		68,543		52,659
	Shares issuable upon vesting/exercise of:
	Options to purchase common stock		188,947		373,899		562,733
	Restricted stock units		588,759		529,312		98,820
	Warrants		3,021,302		6,099,476		1,038,161
			3,805,608		7,071,230		1,752,373

Employee_Benefit_Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2013
Empoyee Benefit Plan [Abstract]	'
Employee Benefit Plan	'
	15. Employee Benefit Plan
	The Company offers employees the opportunity to participate in a 401(k) plan. Through September 30, 2011, the Company matched employee contributions dollar for dollar up to 3% of the employee’s salary during the employee’s period of participation. Such employer contributions are discretionary under the 401(k) plan. As of October 1, 2011, the Company suspended all matching contributions indefinitely. The Company had no expenses related to the employee contribution matching program for the year ended December 31, 2013.  For the years ended December 31, 2012 and 2011, the Company expensed $8,595,  and $395,633, respectively, related to the plan.

Product_Warranty_Provisions

Product Warranty Provisions	12 Months Ended
	Dec. 31, 2013
Product Warranty Provisions [Abstract]	'
Product Warranty Provisions	'
	16. Product Warranty Provisions
	The Company’s standard policy is to warrant all Niobe,  Odyssey and Vdrive systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability as appropriate.
	Accrued warranty, which is included in other accrued liabilities, consists of the following:
		31-Dec-13		31-Dec-12
	Warranty accrual, beginning of the fiscal period	$	653,473	$	691,832
	Warranty expense incurred		84,562		650,367
	Payments made		-236,823		-688,726
	Warranty accrual, end of the fiscal period	$	501,212	$	653,473

Commitments_And_Contingencies

Commitments And Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies [Abstract]	'
Commitments And Contingencies	'
	17. Commitments and Contingencies
	The Company at times becomes a party to claims in the ordinary course of business. Management believes that the ultimate resolution of pending or threatened proceedings will not have a material effect on the financial position, results of operations or liquidity of the Company.
	In 2012, the Company entered into a letter of credit to support a commitment in the amount of approximately $0.1 million. This letter of credit is valid through 2015.

Segment_Information

Segment Information	12 Months Ended
	Dec. 31, 2013
Segment Information [Abstract]	'
Segment Information	'
	18. Segment Information
	The Company considers reporting segments in accordance with general accounting principles for disclosures about segments of an enterprise and related information. The Company’s system and disposable devices are developed and marketed to a broad base of hospitals in the United States and internationally. The Company considers all such sales to be part of a single operating segment.
		Year Ended December 31,
		2013		2012		2011
	United States	$	24,063,932	$	27,034,200	$	23,947,048
	International		13,967,149		19,528,234		18,040,384
	Total	$	38,031,081	$	46,562,434	$	41,987,432
	All of the Company’s long-lived assets are located in the United States. Revenues are attributed to countries based on the location of the customer.

Quarterly_Data_Unaudited

Quarterly Data (Unaudited)	12 Months Ended
	Dec. 31, 2013
Quarterly Data (Unaudited) [Abstract]	'
Quarterly Data (Unaudited)	'
	19. Quarterly Data (Unaudited)
	The following tabulations reflect the unaudited quarterly results of operations for the years ended December 31, 2013 and 2012:
								Basic Net		Diluted Net
						Net Income		Income (Loss)		Income (Loss)
		Net Sales		Gross Profit		(Loss)		Per Share		Per Share
	2013
	First quarter	$	8,408,204	$	6,215,559	$	-4,920,147	$	-0.61	$	-0.61
	Second quarter		9,733,407		7,261,519		-3,006,792		-0.37		-0.37
	Third quarter		10,821,444		7,321,820		-56,868,442		-4.49		-4.49
	Fourth quarter		9,068,026		6,230,882		-3,962,208		-0.23		-0.23
	2012
	First quarter	$	12,283,228	$	8,521,397	$	-5,812,912	$	-1.06	$	-1.06
	Second quarter		10,512,898		7,252,820		2,806,427		0.42		0.32
	Third quarter		11,561,399		8,074,578		-1,915,281		-0.25		-0.25
	Fourth quarter		12,204,909		7,932,584		-4,316,661		-0.55		-0.55

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	20. Subsequent Events
	None.

Valuation_And_Qualifying_Accou

Valuation And Qualifying Accounts	12 Months Ended
	Dec. 31, 2013
Valuation And Qualifying Accounts [Abstract]	'
Valuation And Qualifying Accounts	'
	SCHEDULE II
	VALUATION AND QUALIFYING ACCOUNTS
	FOR THE YEARS ENDED DECEMBER 31, 2013, 2012, AND 2011
				Additions
		Balance at		Charged to
		Beginning of		Cost and				Balance at the
		Year		Expenses		Deductions		End of Year
	Allowance for doubtful accounts and returns:
	Year ended December 31, 2013	$	640,183	$	65,781	$	-322,887	$	383,077
	Year ended December 31, 2012	$	667,529	$	763	$	-28,109	$	640,183
	Year ended December 31, 2011	$	367,536	$	691,459	$	-391,466	$	667,529
	Allowance for inventories valuation:
	Year ended December 31, 2013	$	72,639	$	179,803	$	-172,229	$	80,213
	Year ended December 31, 2012	$	151,157	$	122,783	$	-201,301	$	72,639
	Year ended December 31, 2011	$	539,518	$	156,852	$	-545,213	$	151,157

Summary_Of_Significant_Account1

Summary Of Significant Accounting Policies (Policy)	12 Months Ended
	Dec. 31, 2013
Summary Of Significant Accounting Policies [Abstract]	'
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers all short-term investments purchased with original maturities of three months or less to be cash equivalents. The Company places its cash with high-credit-quality financial institutions and invests primarily in money market accounts. In 2012, we entered into a letter of credit to support a commitment in the amount of approximately $0.1 million. This letter of credit is valid through 2015. No cash was restricted at December 31, 2013 or 2012.
Accounts Receivable and Allowance for Uncollectible Accounts	'
	Accounts Receivable and Allowance for Uncollectible Accounts
	Accounts receivable primarily include amounts due from hospitals and distributors for acquisition of magnetic systems, associated disposable device sales and service contracts. Credit is granted on a limited basis, with balances due generally within 30 days of billing. The provision for bad debts is based upon management’s assessment of historical and expected net collections considering business and economic conditions and other collection indicators.
Financial Instruments	'
	Financial Instruments
	Financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and debt. The carrying value of such amounts reported at the applicable balance sheet dates approximates fair value. See Note 9 for disclosure of the fair value of debt.
	The Company measures certain financial assets and liabilities at fair value on a recurring basis, including warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”).  See Note 12 for disclosure of fair value measurements.
Inventory	'
	Inventory
	The Company values its inventory at the lower of cost, as determined using the first-in, first-out (FIFO) method, or market. The Company periodically reviews its physical inventory for obsolete items and provides a reserve upon identification of potential obsolete items.
Property and Equipment	'
	Property and Equipment
	Property and equipment consist primarily of computer, office, and research and demonstration equipment held for lease and leasehold improvements and are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives or life of the base lease term, ranging from three to ten years.
Long-Lived Assets	'
	Long-Lived Assets
	If facts and circumstances suggest that a long-lived asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value.
Intangible Assets	'
	Intangible Assets
	Intangible assets consist of purchased technology and intellectual property rights valued at cost on the acquisition date and amortized over their estimated useful lives of 10-15 years. If facts and circumstances suggest that an intangible asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and loss during the reporting period. Actual results could differ from those estimates.
Revenue And Costs Of Revenue	'
	Revenue and Costs of Revenue
	The Company adopted Accounting Standards Update 2009-13, Multiple-Deliverable Revenue Arrangements (“ASU 2009-13”) in the fourth quarter of 2009, effective as of January 1, 2009.
	ASU 2009-13 permits management to estimate the selling price of undelivered components of a bundled sale for which it is unable to establish vendor-specific objective evidence (“VSOE”) or third-party evidence (“TPE”). This requires management to record revenue for certain elements of a transaction even though it might not have delivered other elements of the transaction, for which it was unable to meet the requirements for establishing VSOE or TPE. The Company believes that the guidance significantly improves the reporting of these types of transactions to more closely reflect the underlying economic circumstances. This guidance also prohibits the use of the residual method for allocating revenue to the various elements of a transaction and requires that the revenue be allocated proportionally based on the relative estimated selling prices.
	Under our revenue recognition policy, a portion of revenue for Niobe systems, Vdrive systems and certain Odyssey systems is recognized upon delivery, provided that title has passed, there are no uncertainties regarding acceptance, persuasive evidence of an arrangement exists, the sales price is fixed and determinable, and collection of the related receivable is reasonably assured. Revenue is recognized for other types of Odyssey systems upon completion of installation, since there are no qualified third party installers.  When installation is the responsibility of the customer, revenue from system sales is recognized upon shipment since these arrangements do not include an installation element or right of return privileges.  The Company does not recognize revenue in situations in which inventory remains at a Stereotaxis warehouse or in situations in which title and risk of loss have not transferred to the customer. Amounts collected prior to satisfying the above revenue recognition criteria are reflected as deferred revenue.  Revenue from services and license fees, whether sold individually or as a separate unit of accounting in a multiple-deliverable arrangement, is deferred and amortized over the service or license fee period, which is typically one year. Revenue from services is derived primarily from the sale of annual product maintenance plans. We recognize revenue from disposable device sales or accessories upon shipment and establish an appropriate reserve for returns. The return reserve, which is applicable only to disposable devices, is estimated based on historical experience which is periodically reviewed and updated as necessary. In the past, changes in estimate have had only a de minimus effect on revenue recognized in the period. We believe that the estimate is not likely to change significantly in the future.
	Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred.
Research and Development	'
	Research and Development Costs
	Internal research and development costs are expensed in the period incurred. Amounts receivable from strategic alliances under research reimbursement agreements are recorded as a contra-research and development expense in the period reimbursable costs are incurred. There were no material receivables at December 31, 2013 or 2012 under these types of agreements. Advance receipts or other unearned reimbursements are included in accrued liabilities on the accompanying balance sheet until earned.
Share-Based Compensation	'
	Share-Based Compensation
	Stock options or stock appreciation rights issued to certain non-employees are recorded at their fair value as determined in accordance with general accounting principles for share-based payments and accounting for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services, and recognized over the service period. Deferred compensation for options granted to non-employees is remeasured on a quarterly basis through the vesting or forfeiture date.
	The Company utilized the Black-Scholes valuation model to determine the fair value of share-based payments at the date of previously issued grant using risk-free interest rate based on the Treasury yield on the date of the grant and expected volatility based on the Company’s historical volatility over the expected term of the option. The resulting compensation expense is recognized over the requisite service period, generally one to four years. Compensation expense is recognized only for those awards expected to vest, with forfeitures estimated based on the Company’s historical experience and future expectations.
	Restricted shares granted to employees are valued at the fair market value at the date of grant. The Company amortizes the amount to expense over the service period on a straight-line basis for those shares with graded vesting. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives.
	Shares purchased by employees under the 2004 Employee Stock Purchase Plan were considered to be compensatory and were accounted for in accordance with general accounting principles for share-based payments.
Net Loss Per Common Share	'
	Net Loss per Common Share
	Basic loss per common share is computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed by dividing the loss for the period by the weighted average number of common and common equivalent shares outstanding during the period. In addition, the application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable because the Company’s unearned restricted shares do not contractually participate in its losses.
	The Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights or warrants in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because those securities do not contractually participate in its losses.
	On July 10, 2012, the Company effected a one-for-ten reverse stock split of the Company’s common stock.  The net loss per common share, shares outstanding, and weighted average shares outstanding reported in the financial statements and notes to the financial statements for the periods ending December 31, 2013, 2012, and 2011 are presented on a post-split basis.  See Note 11 for additional discussion of the reverse stock split.
	As of December 31, 2013, the Company had 188,947 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $48.38 per share and 3,021,302 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $14.21 per share. The Company had a weighted average of 33,058 unearned restricted shares outstanding for the period ended December 31, 2013.
Income Tax	'
	Income Taxes
	In accordance with general accounting principles for income taxes, a deferred income tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred income tax assets unless, based upon available evidence, it is more likely than not the deferred income tax assets will be realized.
Product Warranty Provisions	'
	Product Warranty Provisions
	The Company’s standard policy is to warrant all systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability (included in other accrued liabilities) as appropriate.
Patent Costs	'
	Patent Costs
	Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain.
Concentrations of Risk	'
	Concentrations of Risk
	The majority of the Company’s cash, cash equivalents and investments are deposited with one major financial institution in the U.S. Deposits in this institution exceed the amount of insurance provided on such deposits.
	One customer, Biosense Webster Inc., as our distributor, accounted for $3,902,178,  $3,447,386, and $3,663,687, or 10%,  7% and 9%, of total net revenue for the years ended December 31, 2013, 2012, and 2011, respectively. No other single customer accounted for more than 10% of total revenue for the year ended December 31, 2013.
Reclassifications	'
	Reclassifications
	Common stock and additional paid-in capital in the prior year’s financial statements have been reclassified to reflect the one-for-ten reverse stock split effected on July 10, 2012. Refer to Note 11 for additional discussion of the reverse stock split.

Inventory_Tables

Inventory (Tables)	12 Months Ended
	Dec. 31, 2013
Inventory [Abstract]	'
Schedule Of Inventory	'
		31-Dec-13	31-Dec-12
	Raw materials	$          3,141,111	$         3,303,053
	Work in process	364,779	65,546
	Finished goods	1,453,362	1,802,281
	Reserve for obsolescence	-80,213	-72,639
	Total inventory	$          4,879,039	$         5,098,241

Prepaid_Expenses_And_Other_Cur1

Prepaid Expenses And Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Prepaid Expenses And Other Current Assets [Abstract]	'
Schedule Of Prepaid Expenses And Other Current Assets	'
		31-Dec-13	31-Dec-12
	Prepaid expenses	$        591,305	$       330,756
	Deferred cost of revenue	72,699	527,725
	Derivative asset	—	1,736
	Deferred financing costs	622,949	1,590,916
	Deposits	658,253	1,040,934
	Total prepaid expenses and other current assets	$     1,945,206	$    3,492,067

Property_And_Equipment_Tables

Property And Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property And Equipment [Abstract]	'
Schedule Of Property And Equipment	'
		December 31,	December 31,
		2013	2012
	Equipment	$          8,143,000	$    8,762,041
	Equipment held for lease	303,412	303,412
	Leasehold improvements	2,328,381	2,328,381
		10,774,793	11,393,834
	Less: Accumulated depreciation	-9,590,204	-9,251,911
	Net property and equipment	$          1,184,589	$    2,141,923

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2013
Accrued Liabilities [Abstract]	'
Schedule Of Accrued Liabilities	'
		December 31,	December 31,
		2013	2012
	Accrued salaries, bonus, and benefits	$     3,565,385	$    2,123,167
	Accrued rent	1,499,942	1,095,641
	Accrued warranties	501,212	653,473
	Accrued interest	498,058	469,049
	Accrued licenses and maintenance fees	302,384	323,901
	Accrued taxes	360,475	245,802
	Other	351,925	450,777
	Total accrued liabilities	$     7,079,381	$    5,361,810

Deferred_Revenue_Tables

Deferred Revenue (Tables)	12 Months Ended
	Dec. 31, 2013
Deferred Revenue [Abstract]	'
Schedule Of Deferred Revenue	'
		December 31,	December 31,
		2013	2012
	Product shipped, revenue deferred	$      1,368,007	$      3,206,641
	Customer deposits	421,544	558,227
	Deferred service and license fees	6,221,283	6,215,230
		8,010,834	9,980,098
	Less: Long-term deferred revenue	-491,080	-477,159
	Total current deferred revenue	$      7,519,754	$      9,502,939

LongTerm_Debt_And_Credit_Facil1

Long-Term Debt And Credit Facilities (Tables)	12 Months Ended
	Dec. 31, 2013
Long-Term Debt And Credit Facilities [Abstract]	'
Schedule Of Long-Term Debt Outstanding	'
		31-Dec-13				31-Dec-12
		Carrying		Estimated		Carrying	Estimated
		Amount		Fair Value		Amount	Fair Value
	Revolving line of credit, due March 2014	$                  -		$                  -		$         7,253,017	$         7,277,084
	Term note, due December 2013	—		—		4,000,000	4,000,000
	Healthcare Royalty Partners debt	18,531,211		18,531,211		16,248,075	16,248,075
	Subordinated convertible debentures	—		—		1,588,134	1,588,134
	Total debt	18,531,211		18,531,211		29,089,226	29,113,293
	Less current maturities	-49,733		-49,733		-12,264,490	-12,288,557
	Total long term debt	$ 18,481,478		$ 18,481,478		$       16,824,736	$       16,824,736
Contractual Principal Maturities Of Debt	'
	2014		$	49,733
	2015			49,733
	2016			49,733
	2017			49,733
	2018			18,332,279
	2019 and Beyond			-
			$	18,531,211	-1
	(1) Future principal payments of Healthcare Royalty Partners debt based on estimated future royalties.

Lease_Obligations_Tables

Lease Obligations (Tables)	12 Months Ended
	Dec. 31, 2013
Lease Obligations [Abstract]	'
Schedule Of Future Minimum Lease Payments	'
			Operating
	Year		Lease
	2014	$	1,593,756
	2015		1,562,353
	2016		1,930,829
	2017		1,981,467
	2018		2,008,832
	Total minimum lease payments	$	9,077,237

Stockholders_Equity_Tables

Stockholder's Equity (Tables)	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity [Abstract]	'
Summary Of Reserved Shares Of Common Stock	'
			December 31,		December 31,
			2013		2012
	Warrants		3,021,302		6,099,476
	Stock award plans		1,032,462		131,464
			4,053,764		6,230,940
Summary Of The Option And Stock Appreciation Rights Activity	'
		Number of Options/SARs		Range of Exercise Price		Weighted Average Exercise Price per Share
	Outstanding, December 31, 2012	373,899		$1.63 - $116.40		$
						43.90
	Granted	-		$0.00 - $0.00		-
	Exercised	-145		$6.80 - $6.80		$
						6.80
	Forfeited	-184,807		$1.69 - $68.60		$
						39.34
	Outstanding, December 31, 2013	188,947		$1.63 - $116.40		$
						48.38
Summary Of The Options And Stock Appreciation Rights Outstanding By Range Of Excercise Price	'
			Year Ended December 31, 2013
										Number of		Weighted
						Weighted		Weighted		Options		Average Exercise
			Options			Average		Average		Currently		Price Per Vested
	Range of Exercise Prices		Outstanding			Remaining Life		Exercise Price		Exercisable		Share
	$0.00 - $20.00			3,975			6.15 years	$	6.04		2,321	$	5.41
	$20.01 - $40.00			92,356			5.32 years	$	35.13		77,390	$	35.08
	$40.01 - $60.00			59,308			2.72 years	$	46.69		56,180	$	46.93
	$60.01 - $90.00			13,408			0.85 years	$	74.04		13,408	$	74.04
	$90.01 - $120.00			19,900			2.21 years	$	106.11		19,900	$	106.11
				188,947			3.88 years	$	48.38		169,199	$	50.05
Summary Of The Restricted Share Grant Activity	'
		Number of Shares		Weighted Average Grant Date Fair Value per Share
	Outstanding, December 31, 2012	68,543		$
				20.62
	Granted	-		-
	Vested	-33		$
				33.80
	Forfeited	-61,910		$
				19.06
	Outstanding, December 31, 2013	6,600		$
				35.20
Summary Of The Restricted Stock Unit Activity	'
		Number of Restricted Stock Units		Weighted Average Grant Date Fair Value per Unit
	Outstanding, December 31, 2012	529,312		$
				2.64
	Granted	449,000		$
				2.20
	Vested	-211,615		$
				3.82
	Forfeited	-177,938		$
				2.09
	Outstanding, December 31, 2013	588,759		$
				2.05
Summary Of The Restricted Shares Outstanding	'
		Number of Shares
	Time based restricted shares	6,600
	Performance based restricted shares	-
	Outstanding, December 31, 2013	6,600

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Measurements [Abstract]	'
Assets And Liabilities Measure At Fair Value On A Recurring Basis By Level	'
		Fair Value Measurement Using
		Total			Quoted Prices in		Significant		Significant
					Active Markets		Other		Unobservable
					for Identical		Observable		Inputs
					Instruments		Inputs		(Level 3)
					(Level 1)		(Level 2)
	Assets at December 31, 2013:
	Cash equivalents	$	11,995,481		11,995,481		—		—
	Total assets at fair value	$	11,995,481		11,995,481		—		—
	Liabilities at December 31, 2013:
	Warrants issued December 29, 2008	$	16,863		—		—		16,863
	Warrants issued May 10, 2012		1,915,753		—		—		1,915,753
	Warrants issued August 2013		3,712,010						3,712,010
	Total liabilities at fair value:	$	5,644,626		—		—		5,644,626
	Assets at December 31, 2012:
	Cash equivalents	$	256,702		256,702		—		—
	Derivative asset		1,736		—		—		1,736
	Total assets at fair value	$	258,438		256,702		—		1,736
	Liabilities at December 31, 2012:
	Warrants issued December 29, 2008	$	71,581		—		—		71,581
	Warrants issued May 10, 2012		2,347,902		—		—		2,347,902
	Derivative liability		548,865		—		—		548,865
	Total liabilities at fair value:	$	2,968,348		—		—		2,968,348
Summary Of Changes In The Fair Value Of The Company's Level 3 Financial Asset And Liabilities	'
		Derivative Asset		Total Assets		Warrants issued December 29, 2008		Warrants issued May 2012		Warrants issued August 2013	Derivative Liability	Total Liabilities
	Balance at beginning of period	$       1,736		$       1,736		$                71,581		$           2,347,902		$                    -	$      548,865	$     2,968,348
	Issues	-		-		-				19,358,108		19,358,108
	Settlements	-		-		-		-18,780,167		-10,535,592	-12,828,650	-42,144,409
	Revaluation	-1,736		-1,736		-54,718		18,348,018		-5,110,506	12,279,785	25,462,579
	Balance at end of period	$               -		$               -		$                16,863		$           1,915,753		$     3,712,010	$                  -	$     5,644,626

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Taxes [Abstract]	'
Schedule of Components of Income Tax Provision	'
		Year Ended December 31,
		2013		2012		2011
	Deferred:
	Federal	$	-93,078,760	$	4,586,506	$	11,367,771
	State and local		-6,128,198		493,946		1,437,062
			-99,206,958		5,080,452		12,804,833
	Valuation allowance		99,206,958		-5,080,452		-12,804,833
		$	—	$	—	$	—
Schedule of Reconciliation of Federal Income Tax Rate	'
		Year Ended December 31,
		2013		2012		2011
	U.S. statutory income tax rate	34.0	%	34	%	34	%
	State and local taxes, net of federal tax benefit	-8.9	%	5.2	%	4.5	%
	Permanent differences between book and tax and other	-169.4	%	14.4	%	1.5	%
	Valuation allowance	144.3	%	-53.6	%	-40	%
	Effective income tax rate	—	%	—	%	—	%
Schedule of Deferred Tax Assets	'
		December 31,
		2013		2012
	Current accruals	$	1,998,086	$	1,753,064
	Depreciation and amortization		2,566,979		2,676,884
	Deferred compensation		5,421,688		5,332,415
	Net operating loss carryovers		28,045,831		127,477,179
	Deferred tax assets		38,032,584		137,239,542
	Valuation allowance		-38,032,584		-137,239,542
	Net deferred tax assets	$	—	$	—

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2013
Net loss per common share:	'
Computation Of Basic And Diluted EPS	'
			2013			2012		2011
	Numerator:
	Numerator for basic EPS		$	-68,757,589		$	-9,238,427	$	-32,031,175
	Effect of dilutive securities
	Numerator for diluted EPS		$	-68,757,589		$	-9,238,427	$	-32,031,175
	Denominator:
	Denominator for basic EPS—weighted average shares			11,554,566			6,944,928		5,482,627
	Effect of dilutive securities
	Denominator for diluted EPS			11,554,566			6,944,928		5,482,627
	Basic EPS		$	-5.95		$	-1.33	$	-5.84
	Diluted EPS		$	-5.95		$	-1.33	$	-5.84
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	'
		December 31,
			2013		2012		2011
	Shares outstanding
	Restricted shares		6,600		68,543		52,659
	Shares issuable upon vesting/exercise of:
	Options to purchase common stock		188,947		373,899		562,733
	Restricted stock units		588,759		529,312		98,820
	Warrants		3,021,302		6,099,476		1,038,161
			3,805,608		7,071,230		1,752,373

Product_Warranty_Provisions_Ta

Product Warranty Provisions (Tables)	12 Months Ended
	Dec. 31, 2013
Product Warranty Provisions [Abstract]	'
Schedule Of Accrued Warranty	'
		31-Dec-13		31-Dec-12
	Warranty accrual, beginning of the fiscal period	$	653,473	$	691,832
	Warranty expense incurred		84,562		650,367
	Payments made		-236,823		-688,726
	Warranty accrual, end of the fiscal period	$	501,212	$	653,473

Segment_Information_Tables

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Information [Abstract]	'
Schedule of Revenue by Geographical Areas	'
		Year Ended December 31,
		2013		2012		2011
	United States	$	24,063,932	$	27,034,200	$	23,947,048
	International		13,967,149		19,528,234		18,040,384
	Total	$	38,031,081	$	46,562,434	$	41,987,432

Quarterly_Data_Tables

Quarterly Data (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Data (Unaudited) [Abstract]	'
Schedule of Quarterly Financial Information	'
								Basic Net		Diluted Net
						Net Income		Income (Loss)		Income (Loss)
		Net Sales		Gross Profit		(Loss)		Per Share		Per Share
	2013
	First quarter	$	8,408,204	$	6,215,559	$	-4,920,147	$	-0.61	$	-0.61
	Second quarter		9,733,407		7,261,519		-3,006,792		-0.37		-0.37
	Third quarter		10,821,444		7,321,820		-56,868,442		-4.49		-4.49
	Fourth quarter		9,068,026		6,230,882		-3,962,208		-0.23		-0.23
	2012
	First quarter	$	12,283,228	$	8,521,397	$	-5,812,912	$	-1.06	$	-1.06
	Second quarter		10,512,898		7,252,820		2,806,427		0.42		0.32
	Third quarter		11,561,399		8,074,578		-1,915,281		-0.25		-0.25
	Fourth quarter		12,204,909		7,932,584		-4,316,661		-0.55		-0.55

Description_Of_Business_Detail

Description Of Business (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013
	item		Scenario, Forecast [Member]	Scenario, Forecast [Member]
			Maximum [Member]	Minimum [Member]
Description Of Business [Line Items]	'	'	'	'
Cumulative losses incurred from inception	($453,403,462)	($384,645,873)	'	'
Installed base	100	'	'	'
Annual plan to rebalance and reduce operating expenses, percentage	'	'	20.00%	15.00%

Summary_Of_Significant_Account2

Summary Of Significant Accounting Policies (Narrative) (Details) (USD $)

0 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

Jul. 10, 2012

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Jul. 10, 2012

Dec. 31, 2013

Jul. 10, 2012

Dec. 31, 2013

Restricted Shares [Member]

Biosense Webster Inc. [Member]

Biosense Webster Inc. [Member]

Biosense Webster Inc. [Member]

Letter of Credit [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Summary Of Significant Accounting Policies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum borrowing capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$100,000

'

'

'

'

Restricted cash

'

0

'

'

'

0

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

Property and equipment, useful life

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'10 years

Intangible assets, useful life

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'15 years

Reverse stock split

0.1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.25

'

0.1

'

Stock options and stock appreciation rights

'

188,947

'

'

'

373,899

'

'

'

188,947

373,899

'

'

'

'

'

'

'

'

'

'

Weighted average exercise price

'

$48.38

'

'

'

$43.90

'

'

'

$48.38

$43.90

'

'

'

'

'

'

'

'

'

'

Common stock issuable upon exercise of outstanding warrants

'

3,021,302

'

'

'

6,099,476

'

'

'

3,021,302

6,099,476

'

'

'

'

'

'

'

'

'

'

Weighted average exercise price of warrants or rights

'

$14.21

'

'

'

'

'

'

'

$14.21

'

'

'

'

'

'

'

'

'

'

'

Weighted average unearned restricted shares outstanding

'

'

'

'

'

'

'

'

'

'

'

'

33,058

'

'

'

'

'

'

'

'

Revenues

'

9,068,026

10,821,444

9,733,407

8,408,204

12,204,909

11,561,399

10,512,898

12,283,228

38,031,081

46,562,434

41,987,432

'

3,902,178

3,447,386

3,663,687

'

'

'

'

'

Major customer, revenue percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

7.00%

9.00%

'

'

'

'

'

Research and development receivable

'

$0

'

'

'

$0

'

'

'

$0

$0

'

'

'

'

'

'

'

'

'

'

Share based compensation, requisite service period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year

'

'4 years

Inventory_Schedule_Of_Inventor

Inventory (Schedule Of Inventory) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Inventory [Abstract]	'	'
Raw materials	$3,141,111	$3,303,053
Work in process	364,779	65,546
Finished goods	1,453,362	1,802,281
Reserve for obsolescence	-80,213	-72,639
Total inventory	$4,879,039	$5,098,241

Prepaid_Expenses_And_Other_Cur2

Prepaid Expenses And Other Current Assets (Schedule Of Prepaid Expenses And Other Current Assets) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Prepaid Expenses And Other Current Assets [Abstract]	'	'
Prepaid expenses	$591,305	$330,756
Deferred cost of revenue	72,699	527,725
Derivative asset	'	1,736
Deferred financing costs	622,949	1,590,916
Deposits	658,253	1,040,934
Total prepaid expenses and other current assets	$1,945,206	$3,492,067

Property_And_Equipment_Schedul

Property And Equipment (Schedule Of Property And Equipment) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Gross property and equipment	$10,774,793	$11,393,834
Less: Accumulated depreciation	-9,590,204	-9,251,911
Net property and equipment	1,184,589	2,141,923
Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Gross property and equipment	8,143,000	8,762,041
Equipment Held For Lease [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Gross property and equipment	303,412	303,412
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Gross property and equipment	$2,328,381	$2,328,381

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Intangible Assets [Abstract]	'	'	'
Total intangible assets, including those subject to execution of agreement	$3,665,000	$3,665,000	'
Accumulated amortization	1,985,514	1,685,680	'
Amortization Expense	299,833	299,833	299,833
Future Amortization Expense, Through July 2018	299,833	'	'
Future Amortization Expense, August 2018 Through May 2020	$166,500	'	'

Accrued_Liabilities_Schedule_O

Accrued Liabilities (Schedule Of Accrued Liabilities) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accrued Liabilities [Abstract]	'	'	'
Accrued salaries, bonus, and benefits	$3,565,385	$2,123,167	'
Accrued rent	1,499,942	1,095,641	'
Accrued warranties	501,212	653,473	691,832
Accrued interest	498,058	469,049	'
Accrued license and maintenance fees	302,384	323,901	'
Accrued taxes	360,475	245,802	'
Other	351,925	450,777	'
Total accrued liabilities	$7,079,381	$5,361,810	'

Deferred_Revenue_Schedule_Of_D

Deferred Revenue (Schedule Of Deferred Revenue) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred Revenue Arrangement [Line Items]	'	'
Deferred revenue	$8,010,834	$9,980,098
Less: Long-term deferred revenue	-491,080	-477,159
Total current deferred revenue	7,519,754	9,502,939
Product Shipped, Revenue Deferred [Member]	'	'
Deferred Revenue Arrangement [Line Items]	'	'
Deferred revenue	1,368,007	3,206,641
Customer Deposits [Member]	'	'
Deferred Revenue Arrangement [Line Items]	'	'
Deferred revenue	421,544	558,227
Deferred Service And License Fees [Member]	'	'
Deferred Revenue Arrangement [Line Items]	'	'
Deferred revenue	$6,221,283	$6,215,230

LongTerm_Debt_And_Credit_Facil2

Long-Term Debt And Credit Facilities (Narrative) (Details) (USD $)

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Aug. 07, 2013

Aug. 07, 2013

Aug. 08, 2013

Dec. 31, 2013

Dec. 31, 2010

Jan. 31, 2013

Nov. 30, 2011

Dec. 31, 2013

31-May-12

Aug. 07, 2013

Dec. 31, 2011

Jul. 31, 2008

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Jul. 31, 2008

Jul. 31, 2008

Jul. 31, 2008

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2010

Convert Warrants [Member]

Exchange Warrants [Member]

Revolving Line Of Credit [Member]

Term Note [Member]

Healthcare Royalty Partners debt [Member]

Healthcare Royalty Partners debt [Member]

Healthcare Royalty Partners debt [Member]

Subordinated Convertible Debentures [Member]

Unconverted Debentures [Member]

Biosense Webster Advance [Member]

Biosense Webster Advance [Member]

2009 Amendment [Member]

2009 Amendment [Member]

November 2010 Agreement [Member]

March 30, 2012 Amendment [Member]

March 30, 2012 Amendment [Member]

May 1, 2012 Agreement [Member]

May 1, 2012 Agreement [Member]

May 10, 2012 Amendment [Member]

May 10, 2012 Amendment [Member]

May 10, 2012 Amendment [Member]

March 2013 Amendment [Member]

March 2013 Amendment [Member]

June 2013 Amendment [Member]

June 2013 Amendment [Member]

July 2013 Amendment [Member]

July 2013 Amendment [Member]

August 2013 Amendment [Member]

August 2013 Amendment [Member]

August 2013 Amendment [Member]

August 2013 Amendment [Member]

September 2011 Amendment [Member]

September 2011 Amendment [Member]

September 2011 Amendment [Member]

Principal Due 2013 [Member]

Principal Due 2012 [Member]

Principal Due 2011 [Member]

Research And Development Expenses [Member]

Royalty Amounts [Member]

Prime Rate Plus [Member]

Prime Rate Plus [Member]

Prime Rate Plus [Member]

Prime Rate Plus [Member]

item

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Subordinated Convertible Debentures [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Term Note [Member]

Term Note [Member]

Term Note [Member]

Term Note [Member]

Term Note [Member]

Biosense Webster Advance [Member]

Biosense Webster Advance [Member]

Biosense Webster Advance [Member]

2009 Amendment [Member]

2009 Amendment [Member]

2010 Amendment To Loan Agreement [Member]

Guarantees From Stockholders [Member]

Guarantees From Stockholders [Member]

Guarantees Provided By Lenders [Member]

Guarantees Provided By Lenders [Member]

Guarantees Provided By Lenders [Member]

Guarantees Provided By Lenders [Member]

Guarantees Provided By Lenders [Member]

Guarantees Provided By Lenders [Member]

Guarantees Provided By Lenders [Member]

Lender's Prime Rate [Member]

Bank's Prime Rate [Member]

Revolving Line Of Credit [Member]

Revolving Line Of Credit [Member]

Term Note [Member]

Guarantees From Stockholders [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum borrowing capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$30,000,000

$10,000,000

$10,000,000

'

$10,000,000

'

$10,000,000

$13,000,000

$3,000,000

'

'

$3,000,000

$6,000,000

$3,000,000

'

$3,000,000

$3,000,000

'

$3,000,000

$0

$20,000,000

'

'

'

'

'

'

'

'

'

'

'

Debt maturity date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31-Mar-12

30-Apr-12

30-Apr-12

15-May-12

15-May-12

31-Mar-13

31-Mar-13

'

30-Jun-13

30-Jun-13

31-Jul-13

31-Jul-13

31-Aug-13

31-Aug-13

'

'

31-Mar-14

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate added to prime rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.50%

5.50%

'

'

'

'

'

0.75%

1.75%

0.50%

3.50%

Accrued interest on facility, floor

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7.00%

6.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Decrease in maximum borrowing capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,333,333

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Earnings before interest and depreciation and amortization revolving credit convenant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-3,000,000

-4,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants

3,021,302

6,099,476

'

'

'

'

'

11,111

'

'

'

2,500,000

'

'

'

'

'

80,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares issued upon conversion of warrants

'

'

'

262,450

'

1,400,000

'

'

'

'

'

'

2,500,000

'

'

'

'

'

'

75,735

'

60,976

'

234,305

'

'

113,636

'

48,387

'

14,313

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate number of shares issued upon conversion

'

'

'

'

2,500,000

800,000

'

'

'

'

'

'

2,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from the exercise of stock warrants

'

'

'

'

8,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants

'

'

'

'

'

'

'

$36

'

'

'

$3.36

$3.36

'

'

'

'

$40.15

'

$6.60

'

$4.10

'

$3.36

'

'

$1.98

'

$1.55

'

$5.24

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrants issued

'

'

'

'

'

'

'

228,332

'

'

'

'

'

'

'

'

'

1,747,392

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Current borrowing capacity

'

'

'

'

'

'

3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit, current availability

'

'

'

'

'

'

3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Paydown of the guarantees

7,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit facility, amount outstanding

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term loan agreement, face value

'

'

'

'

'

'

'

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term loan principal amount due

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000,000

4,000,000

2,000,000

'

'

'

'

'

'

Liquidity ratio

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount borrowed

2,546,328

2,500,000

14,317,397

'

'

'

'

'

'

15,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional amount which may be borrowed

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of royalties entitled to

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Annual interest rate

'

'

'

'

'

'

'

'

'

16.00%

'

8.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional amount borrowed

'

'

'

'

'

'

'

'

2,500,000

'

2,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Convertible Debt

'

'

'

'

'

'

'

'

'

'

'

8,500,000

'

'

'

'

'

'

'

'

'

'

'

'

18,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion price per share

'

'

'

'

'

'

'

'

'

'

'

$3.36

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of convertible shares

'

'

'

'

'

'

'

'

'

'

'

2,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt discount

'

'

'

'

'

'

'

'

'

'

'

7,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrants

'

'

'

'

'

'

'

'

'

'

'

4,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of derivative liability

'

'

'

'

'

'

'

'

'

'

'

3,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Write-off of unamortized discount

5,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Advance on royalty amounts

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,000,000

10,000,000

'

'

'

'

Research and development expenses, Biosense Webster

'

'

'

'

'

'

'

'

'

'

'

'

'

1,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Disposables, service and accessories revenue, Biosense Webster

'

'

'

'

'

'

'

'

'

'

'

'

'

$3,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

LongTerm_Debt_And_Credit_Facil3

Long-Term Debt And Credit Facilities (Schedule Of Long-Term Debt Outstanding) (Details) (USD $)	Dec. 31, 2013		Dec. 31, 2012
Debt Instrument [Line Items]	'		'
Total debt, Carrying Amount	$18,531,211	[1]	$29,089,226
Less current maturities, Carrying Amount	-49,733		-12,264,490
Total long term debt, Carrying Amount	18,481,478		16,824,736
Total debt, Estimated Fair Value	18,531,211		29,113,293
Less current maturities, Estimated Fair Value	-49,733		-12,288,557
Total long term debt, Estimated Fair Value	18,481,478		16,824,736
Revolving Credit Agreement Due March 2014 [Member]	'		'
Debt Instrument [Line Items]	'		'
Total debt, Carrying Amount	'		7,253,017
Total debt, Estimated Fair Value	'		7,277,084
Term Note, Due December 2013 [Member]	'		'
Debt Instrument [Line Items]	'		'
Total debt, Carrying Amount	'		4,000,000
Total debt, Estimated Fair Value	'		4,000,000
Healthcare Royalty Partners debt [Member]	'		'
Debt Instrument [Line Items]	'		'
Total debt, Carrying Amount	18,531,211		16,248,075
Total debt, Estimated Fair Value	18,531,211		16,248,075
Subordinated Convertible Debentures [Member]	'		'
Debt Instrument [Line Items]	'		'
Total debt, Carrying Amount	'		1,588,134
Total debt, Estimated Fair Value	'		$1,588,134
[1]	Future principal payments of Healthcare Royalty Partners debt based on estimated future royalties.

LongTerm_Debt_And_Credit_Facil4

Long-Term Debt And Credit Facilities (Contractual Principal Maturities Of Debt) (Details) (USD $)	Dec. 31, 2013		Dec. 31, 2012
Maturities of Long-term Debt [Abstract]	'		'
2014	$49,733		$12,264,490
2015	49,733		'
2016	49,733		'
2017	49,733		'
2018	18,332,279		'
2019 and Beyond	'		'
Total debt, Carrying Amount	$18,531,211	[1]	$29,089,226
[1]	Future principal payments of Healthcare Royalty Partners debt based on estimated future royalties.

Lease_Obligations_Narrative_De

Lease Obligations (Narrative) (Details) (USD $)	3 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	sqft
Lease Obligations [Abstract]	'	'	'	'
Rent Expense	'	$1,925,813	$1,697,153	$1,711,647
Lease renewal term	'	'3 years	'	'
Area of leased space, terminated	13,000	'	'	'

Lease_Obligations_Schedule_of_

Lease Obligations (Schedule of Future Minimum Lease Payments) (Details) (USD $)	Dec. 31, 2013
Lease Obligations [Abstract]	'
2014	$1,593,756
2015	1,562,353
2016	1,930,829
2017	1,981,467
2018	2,008,832
Total minimum lease payments	$9,077,237

Stockholders_Equity_Narrative_

Stockholders' Equity (Narrative) (Details) (USD $)

0 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

Aug. 07, 2013

Jul. 10, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2009

Jul. 09, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Nov. 27, 2013

Jul. 10, 2012

31-May-12

Dec. 31, 2013

Jul. 10, 2012

Jul. 10, 2012

Jul. 10, 2012

Dec. 31, 2013

Dec. 31, 2011

Aug. 07, 2013

Aug. 07, 2013

Aug. 07, 2013

Aug. 13, 2013

Aug. 16, 2013

Aug. 16, 2013

item

2012 Stock Incentive Plan [Member]

2009 Employee Stock Purchase Plan [Member]

Director [Member]

Initial Grant [Member]

Annual Grants [Member]

Incentive Stock Options [Member]

Incentive Stock Options [Member]

Incentive Stock Options [Member]

Stock Appreciation Rights (SARs) [Member]

Stock Appreciation Rights (SARs) [Member]

Stock Appreciation Rights (SARs) [Member]

Time Based Restricted Shares [Member]

Restricted Stock Units [Member]

Rights [Member]

Pre-Stock Split [Member]

Post-Stock Split [Member]

Post-Stock Split [Member]

Post-Stock Split [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Warrrant Exercise Price $1.98 [Member]

Warrrant Exercise Price $3.361 [Member]

Warrrant Exercise Price $4.10 [Member]

Sanderling Ventures PIPE Warrants [Member]

Franklin Templeton PIPE Warrants [Member]

Alafi Capital Company PIPE Warrants [Member]

Director [Member]

Director [Member]

2012 Stock Incentive Plan [Member]

First Anniversary [Member]

Subsequent Monthly Vesting [Member]

2012 Stock Incentive Plan [Member]

First Anniversary [Member]

2012 Stock Incentive Plan [Member]

2012 Stock Incentive Plan [Member]

2012 Stock Incentive Plan [Member]

2012 Stock Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued, value

'

'

$64,594,513

$10,411,675

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reverse stock split

'

0.1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.25

0.1

'

'

'

'

'

'

'

'

Common stock outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

78,000,000

'

'

7,800,000

'

'

'

'

'

'

'

'

'

'

Common stock authorized

'

'

300,000,000

300,000,000

'

100,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock authorized due to Amendment

'

300,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock par value

'

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares sold in private placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,170,000

'

'

'

'

'

'

'

'

'

'

'

'

Share price of shares sold in private placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.361

'

'

'

'

'

'

'

'

'

'

'

'

Warrants sold in private placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,170,000

'

'

'

'

'

'

'

'

'

'

'

'

Duration period of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'6 years

'

'

'

'

'

'

'

'

'

'

'

Share price of warrants sold in private placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.25

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.36

'

'

'

'

'

'

$1.98

$3.36

$4.10

'

'

'

Net proceeds from sale of securities

'

'

9,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Paydown of the guarantees

'

'

7,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares issued upon conversion of warrants

183,478

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

308,194

'

'

Aggregate number of shares issued upon conversion of subscription rights

262,450

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75,758

156,204

30,488

650,619

650,618

261,241

Proceeds from the exercise of stock warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

2,186,727

878,031

Votes per share

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividends declared

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividends paid

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options, expiration term

'

'

'

'

'

'

'10 years

'

'10 years

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price as percentage of fair value

'

'

'

'

'

'

100.00%

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Option vesting, percentage

'

'

'

'

'

'

'

'

'

'

'

'

25.00%

0.02%

'

'

25.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Option vesting period

'

'

'

'

'

'

'

'

'

'2 years

'1 year

'3 years

'

'

'

'3 years

'

'3 years

'4 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total compensation cost not yet recognized related to options, stock appreciation rights and non-vested stock granted to employees

'

'

1,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated forfeitures

'

'

1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total compensation cost not yet recognized related to options, stock appreciation rights and non-vested stock granted to employees, period of amortization, in years

'

'

'4 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options To Purchase Common Stock

'

'

188,947

373,899

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average remaining life

'

'

'3 years 10 months 17 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average exercise price per vested share

'

'

$50.05

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of options currently exercisable

'

'

169,199

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average remaining life of vested options outstanding

'

'

'3 years 8 months 9 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options and stock appreciation rights in-the-money

'

'

1,625

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intrinsic value of options and stock appreciation rights outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

Closing stock price

'

'

$3.62

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intrinsic value of options and stock appreciation rights exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

Grants in period

'

'

0

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from options exercised

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

100,000

'

'

'

'

'

'

Intrinsic value of restricted shares outstanding

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intrinsic value of restricted stock units outstanding

'

'

2,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intrinsic value of vested restricted shares

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intrinsic value of vested restricted stock units

'

'

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Adjustment for unmet performance conditions

'

'

-200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Adjustment for forfiture rate,

'

'

-500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares authorized under plan

'

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of compensation eligible employees can use to purchase common stock, maximum

'

'

'

'

15.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Compensation amount eligible employees can use to purcahse common stock, maximum

'

'

'

'

$25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of fair value eligible employees can purchase common stock

'

'

'

'

95.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares available under ESPP

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Summary_Of

Stockholders' Equity (Summary Of Reserved Shares Of Common Stock) (Details)	Dec. 31, 2013	Dec. 31, 2012
Stockholders' Equity [Abstract]	'	'
Warrants	3,021,302	6,099,476
Stock award plans	1,032,462	131,464
Total Reserved Shares of Common Stock	4,053,764	6,230,940

Stockholders_Equity_Summary_Of1

Stockholders' Equity (Summary Of The Option And Stock Appreciation Rights Activity) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Number of Options/SARs, Outstanding, December 31, 2012	373,899	'
Number of Options/SARs, Exercised	-145	'
Number of Options/SARs, Forfeited	-184,807	'
Number of Options/SARs, Outstanding, December 31, 2013	188,947	'
Weighted Average Exercise Price per Share, Outstanding, December 31, 2012	$43.90	'
Weighted Average Exercise Price per Share, Exercised	$6.80	'
Weighted Average Exercise Price per Share, Forfeited	$39.34	'
Weighted Average Exercise Price per Share, Outstanding, December 31, 2013	$48.38	'
Minimum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price, Outstanding, December 31, 2012	$1.63	$1.63
Range of Exercise Price, Granted	$0	'
Range of Exercise Price, Exercised	$6.80	'
Range of Exercise Price, Forfeited	$1.69	'
Range of Exercise Price, Outstanding, December 31, 2013	$1.63	$1.63
Maximum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price, Outstanding, December 31, 2012	$116.40	$116.40
Range of Exercise Price, Granted	$0	'
Range of Exercise Price, Exercised	$6.80	'
Range of Exercise Price, Forfeited	$68.60	'
Range of Exercise Price, Outstanding, December 31, 2013	$116.40	$116.40

Stockholders_Equity_Summary_Of2

Stockholders' Equity (Summary Of The Option And Stock Appreciation Rights Outstanding) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Number of Options/SARs, Outstanding, December 31, 2013	188,947	373,899
Weighted average remaining life	'3 years 10 months 17 days	'
Weighted Average Exercise Price per Share, Outstanding, December 31, 2013	$48.38	$43.90
Number of options currently exercisable	169,199	'
Weighted average exercise price per vested share	$50.05	'
$0.00 - $20.00 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Range of Exercise Price, Lower limit	$0	'
Range of Exercise Price, Upper limit	$20	'
Number of Options/SARs, Outstanding, December 31, 2013	3,975	'
Weighted average remaining life	'6 years 1 month 24 days	'
Weighted Average Exercise Price per Share, Outstanding, December 31, 2013	$6.04	'
Number of options currently exercisable	2,321	'
Weighted average exercise price per vested share	$5.41	'
$20.01 - $40.00 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Range of Exercise Price, Lower limit	$20.01	'
Range of Exercise Price, Upper limit	$40	'
Number of Options/SARs, Outstanding, December 31, 2013	92,356	'
Weighted average remaining life	'5 years 3 months 26 days	'
Weighted Average Exercise Price per Share, Outstanding, December 31, 2013	$35.13	'
Number of options currently exercisable	77,390	'
Weighted average exercise price per vested share	$35.08	'
$40.01 - $60.00 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Range of Exercise Price, Lower limit	$40.01	'
Range of Exercise Price, Upper limit	$60	'
Number of Options/SARs, Outstanding, December 31, 2013	59,308	'
Weighted average remaining life	'2 years 8 months 19 days	'
Weighted Average Exercise Price per Share, Outstanding, December 31, 2013	$46.69	'
Number of options currently exercisable	56,180	'
Weighted average exercise price per vested share	$46.93	'
$60.01 - $90.00 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Range of Exercise Price, Lower limit	$60.01	'
Range of Exercise Price, Upper limit	$90	'
Number of Options/SARs, Outstanding, December 31, 2013	13,408	'
Weighted average remaining life	'10 months 6 days	'
Weighted Average Exercise Price per Share, Outstanding, December 31, 2013	$74.04	'
Number of options currently exercisable	13,408	'
Weighted average exercise price per vested share	$74.04	'
$90.01 - $120.00 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Range of Exercise Price, Lower limit	$90.01	'
Range of Exercise Price, Upper limit	$120	'
Number of Options/SARs, Outstanding, December 31, 2013	19,900	'
Weighted average remaining life	'2 years 2 months 16 days	'
Weighted Average Exercise Price per Share, Outstanding, December 31, 2013	$106.11	'
Number of options currently exercisable	19,900	'
Weighted average exercise price per vested share	$106.11	'

Stockholders_Equity_Summary_Of3

Stockholders' Equity (Summary Of The Restricted Share Grant Activity) (Details) (Restricted Shares [Member], USD $)	12 Months Ended
	Dec. 31, 2013
Restricted Shares [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of Shares, Outstanding, December 31, 2012	68,543
Number of Shares, Granted	'
Number of Shares, Vested	-33
Number of Shares, Forfeited	-61,910
Number of Shares, Outstanding, December 31, 2013	6,600
Weighted Average Grant Date Fair Value per Share/Unit, Outstanding, December 31, 2012	$20.62
Weighted Average Grant Date Fair Value per Share/Unit, Granted	'
Weighted Average Grant Date Fair Value per Share/Unit, Vested	$33.80
Weighted Average Grant Date Fair Value per Share/Unit, Forfeited	$19.06
Weighted Average Grant Date Fair Value per Share/Unit, Outstanding, December 31, 2013	$35.20

Stockholders_Equity_Summary_Of4

Stockholders' Equity (Summary Of The Restricted Stock Unit Activity) (Details) (Restricted Stock Units [Member], USD $)	12 Months Ended
	Dec. 31, 2013
Restricted Stock Units [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of Shares, Outstanding, December 31, 2012	529,312
Number of Shares, Granted	449,000
Number of Shares, Vested	-211,615
Number of Shares, Forfeited	-177,938
Number of Shares, Outstanding, December 31, 2013	588,759
Weighted Average Grant Date Fair Value per Share/Unit, Outstanding, December 31, 2012	$2.64
Weighted Average Grant Date Fair Value per Share/Unit, Granted	$2.20
Weighted Average Grant Date Fair Value per Share/Unit, Vested	$3.82
Weighted Average Grant Date Fair Value per Share/Unit, Forfeited	$2.09
Weighted Average Grant Date Fair Value per Share/Unit, Outstanding, December 31, 2013	$2.05

Stockholders_Equity_Summary_Of5

Stockholders' Equity (Summary Of The Restricted Shares Outstanding) (Details) (Restricted Shares [Member])	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Restricted stock outstanding	6,600	68,543
Time Based Restricted Shares [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Restricted stock outstanding	6,600	'

Fair_Value_Measurements_Narrat

Fair Value Measurements (Narrative) (Details) (USD $)

12 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Aug. 31, 2013

Dec. 31, 2013

Aug. 31, 2013

Dec. 31, 2013

10-May-12

Dec. 31, 2013

Dec. 31, 2012

Dec. 29, 2008

Aug. 07, 2013

Dec. 31, 2013

Common Stock Closes Above $15.00 [Member]

Common Stock Closes Above $15.00 [Member]

Common Stock Closes Above $20.00 [Member]

Common Stock Closes Above $20.00 [Member]

Black-Scholes Model Used to Value Warrants [Member]

Monte-Carlo Simulation Used To Value Derivative Assets And Liabilities [Member]

Fair Value, Inputs, Level 1 [Member]

Fair Value, Inputs, Level 1 [Member]

Fair Value, Inputs, Level 3 [Member]

Exchange Warrants [Member]

PIPE Warrants [Member]

Monte-Carlo Simulation Used To Value Derivative Assets And Liabilities [Member]

Fair Value Measurements [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash equivalents invested in money market funds

$11,995,481

$256,702

'

'

'

'

'

'

$11,995,481

$256,702

'

'

'

Issued warrants to purchase shares of common stock

3,021,302

6,099,476

'

'

'

'

'

'

'

'

179,241

'

'

Fair value of warrants issued

'

'

'

'

'

'

16,863

'

'

'

'

'

'

Dividend yield

'

'

'

'

'

'

0.00%

'

'

'

'

'

'

Volatility rate

'

'

'

'

'

'

112.66%

80.00%

'

'

'

111.00%

142.28%

Risk-free interest rate

'

'

'

'

'

'

0.78%

1.04%

'

'

'

1.46%

1.75%

Expected life

'

'

'

'

'

'

'6 months

'

'

'

'

'

'

Closing stock price

$3.62

'

'

'

'

'

'

$3.41

'

'

'

$8.69

$3.62

Mandatory conversion percentage per Debentures agreement

'

'

'

50.00%

'

100.00%

'

'

'

'

'

'

'

Share price which determines conversion per Debentures agreement

'

'

'

15

'

20

'

'

'

'

'

'

'

Number of consecutive trading days required at stock price

'

'

'20 days

'

'20 days

'

'

'

'

'

'

'

'

Mandatory conversion minimum per Debentures agreement

'

'

'

$2,500,000

'

$2,500,000

'

'

'

'

'

'

'

Fair_Value_Measurements_Assets

Fair Value Measurements (Assets And Liabilities Measure At Fair Value On A Recurring Basis By Level) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	$11,995,481	$256,702
Derivative asset	'	1,736
Total Assets at Fair Value	11,995,481	258,438
Derivative liability	'	548,865
Total Liabilities at Fair Value	5,644,626	2,968,348
Warrants Issued December 29, 2008 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of warrants issued	16,863	71,581
Warrants Issued May 10, 2012 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of warrants issued	1,915,753	2,347,902
Warrants Issued August 2013 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of warrants issued	3,712,010	'
Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	11,995,481	256,702
Total Assets at Fair Value	11,995,481	256,702
Fair Value, Inputs, Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	'	'
Derivative asset	'	'
Total Assets at Fair Value	'	'
Derivative liability	'	'
Total Liabilities at Fair Value	'	'
Fair Value, Inputs, Level 2 [Member] | Warrants Issued December 29, 2008 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of warrants issued	'	'
Fair Value, Inputs, Level 2 [Member] | Warrants Issued May 10, 2012 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of warrants issued	'	'
Fair Value, Inputs, Level 2 [Member] | Warrants Issued August 2013 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of warrants issued	'	'
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Derivative asset	'	1,736
Total Assets at Fair Value	'	1,736
Derivative liability	'	548,865
Total Liabilities at Fair Value	5,644,626	2,968,348
Fair Value, Inputs, Level 3 [Member] | Warrants Issued December 29, 2008 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of warrants issued	16,863	71,581
Fair Value, Inputs, Level 3 [Member] | Warrants Issued May 10, 2012 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of warrants issued	1,915,753	2,347,902
Fair Value, Inputs, Level 3 [Member] | Warrants Issued August 2013 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of warrants issued	$3,712,010	'

Fair_Value_Measurements_Summar

Fair Value Measurements (Summary Of Changes In The Fair Value Of The Company's Level 3 Financial Asset And Liabilities) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Assets, Balance at beginning of period	$1,736
Assets, Revaluation	-1,736
Liabilities, Balance at beginning of period	2,968,348
Liabilities, Issues	19,358,108
Liabilities, Settlements	-42,144,409
Liabilities, Revaluations	25,462,579
Liabilities, Balance at end of period	5,644,626
Warrants Issued December 29, 2008 [Member]	'
Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Liabilities, Balance at beginning of period	71,581
Liabilities, Revaluations	-54,718
Liabilities, Balance at end of period	16,863
Warrants Issued May 10, 2012 [Member]	'
Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Liabilities, Balance at beginning of period	2,347,902
Liabilities, Settlements	-18,780,167
Liabilities, Revaluations	18,348,018
Liabilities, Balance at end of period	1,915,753
Warrants Issued August 2013 [Member]	'
Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Liabilities, Issues	19,358,108
Liabilities, Settlements	-10,535,592
Liabilities, Revaluations	-5,110,506
Liabilities, Balance at end of period	3,712,010
Derivative Liability [Member]	'
Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Liabilities, Balance at beginning of period	548,865
Liabilities, Settlements	-12,828,650
Liabilities, Revaluations	12,279,785
Derivative Asset [Member]	'
Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Assets, Balance at beginning of period	1,736
Assets, Revaluation	($1,736)

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Operating Loss Carryforwards [Line Items]	'	'
Valid portion of valuation allowance, percentage	100.00%	'
Number of prior years subject to examination	'10 years	'
Accrued interest and penalties	$0	'
Reserves for uncertain tax positions	200,000	200,000
Federal [Member]	'	'
Operating Loss Carryforwards [Line Items]	'	'
Operating loss carryforwards	75,800,000	'
State [Member]	'	'
Operating Loss Carryforwards [Line Items]	'	'
Operating loss carryforwards	$2,300,000	'

Income_Taxes_Provision_For_Inc

Income Taxes (Provision For Income Taxes) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Taxes [Abstract]	'	'	'
Federal	($93,078,760)	$4,586,506	$11,367,771
State and local	-6,128,198	493,946	1,437,062
Deferred Income Tax Expense (Benefit), Total	-99,206,958	5,080,452	12,804,833
Valuation allowance	99,206,958	-5,080,452	-12,804,833
Income Tax Benefit	'	'	'

Income_Taxes_Schedule_of_Recon

Income Taxes (Schedule of Reconciliation of Federal Income Tax Rate) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Taxes [Abstract]	'	'	'
U.S. statutory income tax rate	34.00%	34.00%	34.00%
State and local taxes, net of federal tax benefit	-8.90%	5.20%	4.50%
Permanent differences between book and tax and other	-169.40%	14.40%	1.50%
Valuation allowance	144.30%	-53.60%	-40.00%
Effective income tax rate	'	'	'

Income_Taxes_Schedule_of_Defer

Income Taxes (Schedule of Deferred Tax Asset) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Income Taxes [Abstract]	'	'
Current accruals	$1,998,086	$1,753,064
Depreciation and amortization	2,566,979	2,676,884
Deferred compensation	5,421,688	5,332,415
Net operating loss carryovers	28,045,831	127,477,179
Deferred tax assets	38,032,584	137,239,542
Valuation allowance	-38,032,584	-137,239,542
Net deferred tax assets	'	'

Net_Loss_Per_Share_Computation

Net Loss Per Share (Computation of Basic and Diluted EPS) (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Net loss per common share:	'	'	'	'	'	'	'	'	'	'	'
Numerator for basic EPS	($3,962,208)	($56,868,442)	($3,006,792)	($4,920,147)	($4,316,661)	($1,915,281)	$2,806,427	($5,812,912)	($68,757,589)	($9,238,427)	($32,031,175)
Effect of dilutive securities	'	'	'	'	'	'	'	'	'	'	'
Numerator for diluted EPS	'	'	'	'	'	'	'	'	($68,757,589)	($9,238,427)	($32,031,175)
Denominator for basic EPS - weighted average shares	'	'	'	'	'	'	'	'	11,554,566	6,944,928	5,482,627
Effect of dilutive securities	'	'	'	'	'	'	'	'	'	'	'
Denominator for diluted EPS	'	'	'	'	'	'	'	'	11,554,566	6,944,928	5,482,627
Basic EPS	($0.23)	($4.49)	($0.37)	($0.61)	($0.55)	($0.25)	$0.42	($1.06)	($5.95)	($1.33)	($5.84)
Diluted EPS	($0.23)	($4.49)	($0.37)	($0.61)	($0.55)	($0.25)	$0.32	($1.06)	($5.95)	($1.33)	($5.84)

Net_Loss_Per_Share_Schedule_of

Net Loss Per Share (Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,805,608	7,071,230	1,752,373
Restricted Shares [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,600	68,543	52,659
Options to Purchase Common Stock [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	188,947	373,899	562,733
Restricted Stock Units [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	588,759	529,312	98,820
Warrants [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,021,302	6,099,476	1,038,161

Employee_Benefit_Plan_Details

Employee Benefit Plan (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Empoyee Benefit Plan [Abstract]	'	'
Maximum employer match of eligible contributions	3.00%	'
Defined Contribution Plan, Cost Recognized	$8,595	$395,633

Product_Warranty_Provisions_Sc

Product Warranty Provisions (Schedule Of Accrued Warranty) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Product Warranty Provisions [Abstract]	'	'
Warranty accrual, beginning of the fiscal period	$653,473	$691,832
Warranty expense incurred	84,562	650,367
Payments made	-236,823	-688,726
Warranty accrual, end of the fiscal period	$501,212	$653,473

Commitments_And_Contingencies_

Commitments And Contingencies (Details) (USD $)	Dec. 31, 2012
In Millions, unless otherwise specified
Commitments And Contingencies [Abstract]	'
Letter of credit	$0.10

Segment_Information_Details

Segment Information (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
International	'	'	'	'	'	'	'	'	'	'	'
Total revenue	$9,068,026	$10,821,444	$9,733,407	$8,408,204	$12,204,909	$11,561,399	$10,512,898	$12,283,228	$38,031,081	$46,562,434	$41,987,432
United States [Member]	'	'	'	'	'	'	'	'	'	'	'
International	'	'	'	'	'	'	'	'	'	'	'
Total revenue	'	'	'	'	'	'	'	'	24,063,932	27,034,200	23,947,048
International [Member]	'	'	'	'	'	'	'	'	'	'	'
International	'	'	'	'	'	'	'	'	'	'	'
Total revenue	'	'	'	'	'	'	'	'	$13,967,149	$19,528,234	$18,040,384

Quarterly_Data_Details

Quarterly Data (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Data (Unaudited) [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Revenues	$9,068,026	$10,821,444	$9,733,407	$8,408,204	$12,204,909	$11,561,399	$10,512,898	$12,283,228	$38,031,081	$46,562,434	$41,987,432
Gross Profit	6,230,882	7,321,820	7,261,519	6,215,559	7,932,584	8,074,578	7,252,820	8,521,397	27,029,780	31,781,379	29,489,351
Net Loss	($3,962,208)	($56,868,442)	($3,006,792)	($4,920,147)	($4,316,661)	($1,915,281)	$2,806,427	($5,812,912)	($68,757,589)	($9,238,427)	($32,031,175)
Basic EPS	($0.23)	($4.49)	($0.37)	($0.61)	($0.55)	($0.25)	$0.42	($1.06)	($5.95)	($1.33)	($5.84)
Diluted EPS	($0.23)	($4.49)	($0.37)	($0.61)	($0.55)	($0.25)	$0.32	($1.06)	($5.95)	($1.33)	($5.84)

Valuation_And_Qualifying_Accou1

Valuation And Qualifying Accounts (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Allowance For Doubtful Accounts And Returns [Member]	'	'	'
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'
Balance at Beginning of Year	$640,183	$667,529	$367,536
Additions Charged to Cost and Expenses	65,781	763	691,459
Deductions	-322,887	-28,109	-391,466
Balance at the End of Year	383,077	640,183	667,529
Allowance For Inventory Valuation [Member]	'	'	'
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'
Balance at Beginning of Year	72,639	151,157	539,518
Additions Charged to Cost and Expenses	179,803	122,783	156,852
Deductions	-172,229	-201,301	-545,213
Balance at the End of Year	$80,213	$72,639	$151,157